Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides

ABSTRACT

Disclosed are methods of reducing the incidence of necrotizing enterocolitis in an infant, toddler, or child using nutritional compositions including human milk oligosaccharides. The nutritional compositions including the human milk oligosaccharides are effective in reducing inflammation and the incidence of inflammatory diseases.

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application No.61/428,863 filed on Dec. 31, 2010; and U.S. Provisional Application No.61/428,868 filed on Dec. 31, 2010, which disclosures are incorporated byreference in their entirety.

FIELD OF THE DISCLOSURE

The present disclosure relates to human milk oligosaccharides (HMOs) forimproving gastrointestinal function and tolerance in infants, toddlers,and children. More particularly, the present disclosure relates to humanmilk fortifiers, preterm and term infant formulas, and pediatricformulas comprising HMOs that can stimulate enteric nerve cells in thegastrointestinal tract, thereby treating and/or preventing numerousgastrointestinal-related conditions and diseases.

BACKGROUND OF THE DISCLOSURE

During postnatal development, a newborn's intestine experiences aprocess of maturation that ends with the production of gastrointestinalepithelium that functions as a selective barrier (i.e., gut barrier).The gastrointestinal epithelium permits the absorption of nutrients,electrolytes and water, while preventing exposure to dietary andmicrobial antigens, including food allergens. Specifically, this barrierlimits the passage of antigens to the systemic circulation, therebypreventing infection, inflammatory reactions, and other gastrointestinaldiseases and disorders that may occur during infancy and later in life.For very young infants, and particularly, preterm infants, who have animmature immune system and intestinal tract, development of suboptimalintestinal flora may result in infection, diarrhea, allergies, and foodintolerance.

Barrier formation and maintenance has been found to be affected by thediet. Breast milk contains components that not only act as pathogenreceptor analogues, but also activate immune factors by infantintestinal epithelial cells and/or associated immune cell populations toenhance development and maturation of the infant's gastrointestinal andimmune systems.

Not all infants, however, are in a position to receive human breastmilk. It would therefore be desirable to provide nutritionalcompositions, and synthetic infant formulas in particular, that canproduce nutritional benefits including improved gastrointestinal growth,development, and maturation. It would additionally be beneficial if thenutritional compositions could enhance immunity against microbialinfections and other gastrointestinal diseases, conditions, anddisorders.

SUMMARY OF THE DISCLOSURE

The present disclosure is directed to nutritional compositions,including synthetic infant formulas, synthetic pediatric formulas, andsynthetic child formulas including at least one HMO alone or incombination with other components such as prebiotic oligosaccharidesand/or probiotics, for improving gut function and immunity in an infant,toddler, child, or adult, along with related methods of use. Moreparticularly, the nutritional compositions can improve growth andmaturation of the gut barrier, thereby treating and/or preventingformula intolerance or other gastrointestinal diseases and/or disordersresulting from a loss of dysfunction of the gut barrier.

One embodiment is directed to a method of reducing the incidence ofnecrotizing enterocolitis in an infant, toddler, or child in needthereof. The method comprises administering to the infant, toddler, orchild a composition comprising human milk oligosaccharides in a totalamount of from about 0.001 mg/mL to about 20 mg/mL.

Another embodiment is directed to a method of reducing the incidence ofnecrotizing enterocolitis in an infant, toddler, or child in needthereof. The method comprises administering to the infant, toddler, orchild a nutritional composition comprising 6′-sialyllactose,2′-fucosyllactose, and lacto-N-neotetraose.

Another embodiment is directed to a synthetic formula for improving thefeeding intolerance of an infant, toddler, or child in need thereof Thesynthetic formula comprises from about 0.2 mg/mL to about 20 mg/mL of anoligosaccharide blend, wherein the oligosaccharide blend comprises afirst oligosaccharide selected from the group consisting of afructooligosaccharide, a galactooligosaccharide, lacto-N-neotetraose,2′-fucosyllactose, and combinations thereof a second oligosaccharideselected from the group consisting of 3′-sialyllactose,6′-sialyllactose, and combinations thereof and a third oligosaccharideselected from the group consisting of inulin, a gum, polydextrose, andcombinations thereof.

Another embodiment is directed to a synthetic formula for improving thefeeding intolerance of an infant, toddler, or child in need thereof Thesynthetic formula comprises from about 0.2 mg/mL to about 20 mg/mL of anoligosaccharide blend, wherein the oligosaccharide blend comprises afirst oligosaccharide selected from the group consisting of afructooligosaccharide, a galactooligosaccharide, lacto-N-neotetraose,2′-fucosyllactose, and combinations thereof and a second oligosaccharideselected from the group consisting of 3′-sialyllactose,6′-sialyllactose, and combinations thereof.

Another embodiment is directed to a method of improving the feedingtolerance of an infant, toddler, or child in need thereof The methodcomprises administering to the infant, toddler, or child a nutritionalcomposition comprising from about 0.2 mg/mL to about 20 mg/mL of anoligosaccharide blend, wherein the oligosaccharide blend comprises afirst oligosaccharide selected from the group consisting of afructooligosaccharide, a galactooligosaccharide, lacto-N-neotetraose,2′-fucosyllactose, and combinations thereof; a second oligosaccharideselected from the group consisting of 3′-sialyllactose,6′-sialyllactose, and combinations thereof; and a third oligosaccharideselected from the group consisting of inulin, a gum, polydextrose, andcombinations thereof.

Another embodiment is directed to a method of improving the feedingtolerance of an infant, toddler, or child in need thereof. The methodcomprises administering to the infant, toddler, or child a syntheticpediatric formula comprising from about 0.2 mg/mL to about 20 mg/mL ofan oligosaccharide blend, wherein the oligosaccharide blend comprises afirst oligosaccharide selected from the group consisting of afructooligosaccharide, a galactooligosaccharide, lacto-N-neotetraose,2′-fucosyllactose, and combinations thereof; a second oligosaccharideselected from the group consisting of 3′-sialyllactose,6′-sialyllactose, and combinations thereof; and a third oligosaccharideselected from the group consisting of inulin, a gum, polydextrose, andcombinations thereof.

It has been discovered that HMOs that are delivered to the gut tissuestimulate the gut-brain-immune axis, and improve the immune system andenteric nervous system. Specifically, it has been found that2′-fucosyllactose stimulates enteric nerve cells in the gastrointestinaltract such that gut function may be improved and gastrointestinal issuesminimized.

Additionally, it has been found that the digestive tolerance of aninfant, toddler, child, or adult can be significantly increased byadministering to the infant, toddler, child or adult a select blend ofcarbohydrates including HMOs. Specifically, the carbohydrate blendincludes a combination of fast, medium, and slowly digestedcarbohydrates including specific HMOs such as lacto-N-neotetraose,2′-fucosyllactose, 3′-fucosyllactose, 3′-sialyllactose and/or6′-sailyllactose.

Moreover, it has been found that intestinal barrier integrity of aninfant, toddler, child, or adult can be significantly improved byadministering to the infant, toddler, child, or adult a synbioticcomposition including HMOs. Specifically, the synbiotic combinationincludes a probiotic, at least one of a galactooligosaccharide and afructooligosaccharide (such as a short chain fructooligosaccharide) andat least one HMO. The synbiotic composition promotes the colonization ofbeneficial intestinal microbiota in order to discourage the growth ofharmful bacteria.

Although the nutritional compositions and methods are primarilydiscussed herein in relation to preterm infants and infants in general,it should be understood that many of the benefits discussed herein maybe provided to toddlers, children, and adults administered combinationsof the HMOs alone, or with other components as described herein, such asprebiotic oligosaccharides and/or probiotics, for example. Particularly,in some embodiments, the incidence of gastrointestinal diseases anddisorders that generally affect adults, such as Crohn's disease,irritable bowel syndrome and the like, can be reduced with the use ofthe nutritional compositions of the present disclosure including HMOs.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a graph depicting the effect of 2′FL and 3′FL on gut motilityas measured in Example 35.

FIG. 2 is a table setting forth the microbiological medium used in thein vitro experiment of Example 36.

FIG. 3 is a graph depicting the change in pH over time as affected bythe various oligosaccharide substrates as tested in Example 36.

FIG. 4 is a graph depicting change in short chain fatty acid productionover time as affected by the various oligosaccharide substrates astested in Example 36.

FIG. 5A depicts growth curves of various Bifidobacterium spp. asevaluated in Example 37.

FIG. 5B depicts growth curves of various Bifidobacterium spp. asevaluated in Example 37.

FIG. 5C depicts growth curves of various Bifidobacterium spp. asevaluated in Example 37.

FIG. 5D depicts growth curves of various Bifidobacterium spp. asevaluated in Example 37.

FIG. 5E depicts growth curves of various Bifidobacterium spp. asevaluated in Example 37.

FIG. 5F depicts growth curves of various Bifidobacterium spp. asevaluated in Example 37.

FIG. 5G depicts growth curves of various Bifidobacterium spp. asevaluated in Example 37.

FIG. 5H depicts growth curves of various Bifidobacterium spp. asevaluated in Example 37.

FIG. 6A depicts growth curves of various Bifidobacterium spp. asevaluated in Example 37.

FIG. 6B depicts growth curves of various Bifidobacterium spp. asevaluated in Example 37.

FIG. 6C depicts growth curves of various Bifidobacterium spp. asevaluated in Example 37.

FIG. 6D depicts growth curves of various Bifidobacterium spp. asevaluated in Example 37.

FIG. 6E depicts growth curves of various Bifidobacterium spp. asevaluated in Example 37.

FIG. 6F depicts growth curves of various Bifidobacterium spp. asevaluated in Example 37.

FIG. 6G depicts growth curves of various Bifidobacterium spp. asevaluated in Example 37.

FIG. 6H depicts growth curves of various Bifidobacterium spp. asevaluated in Example 37.

FIG. 7A depicts growth curves of various Bifidobacterium spp. asevaluated in Example 37.

FIG. 7B depicts growth curves of various Bifidobacterium spp. asevaluated in Example 37.

FIG. 7C depicts growth curves of various Bifidobacterium spp. asevaluated in Example 37.

FIG. 7D depicts growth curves of various Bifidobacterium spp. asevaluated in Example 37.

FIG. 7E depicts growth curves of various Bifidobacterium spp. asevaluated in Example 37.

FIG. 7F depicts growth curves of various Bifidobacterium spp. asevaluated in Example 37.

FIG. 7G depicts growth curves of various Bifidobacterium spp. asevaluated in Example 37.

FIG. 8 is a graph showing Pre-confluent HT-29 epithelial celldifferentiation in the presence of LNnT, 2′FL, and 6′SL.

FIG. 9 is a graph showing Pre-confluent HT-29 epithelial celldifferentiation in the presence of LNnT, 2′FL, and 6′SL.

FIG. 10 is a graph showing Pre-confluent HT-29 epithelial celldifferentiation in the presence of LNnT, 2′FL, and 6′SL.

FIG. 11 is a graph showing Confluent HT-29 epithelial cell resistance inthe presence of LNnT, 2′FL, and 6′SL.

FIG. 12 is a graph showing Confluent HT-29 epithelial cell resistance inthe presence of LNnT, 2′FL, and 6′SL.

FIG. 13 is a graph showing Confluent HT-29 epithelial cell resistance inthe presence of LNnT, 2′FL, and 6′SL.

FIG. 14 is a graph showing Post-confluent CaCo-2Bbe epithelial celldifferentiation in the presence of LNnT, 2′FL, and 6′SL.

FIG. 15 is a graph showing Post-confluent CaCo-2Bbe epithelial celldifferentiation in the presence of LNnT, 2′FL, and 6′SL.

FIG. 16 is a graph showing Post-confluent CaCo-2Bbe epithelial celldifferentiation in the presence of LNnT, 2′FL, and 6′SL.

FIG. 17 is a graph showing Post-confluent CaCo-2Bbe epithelial cellsucrase activity in the presence of LNnT, 2′FL, and 6′SL.

FIG. 18 is a graph showing Post-confluent CaCo-2Bbe epithelial cellsucrase activity in the presence of LNnT, 2′FL, and 6′SL.

FIG. 19 is a graph showing Post-confluent CaCo-2Bbe epithelial cellsucrase activity in the presence of LNnT, 2′FL, and 6′SL.

FIG. 20 is a graph showing Post-confluent CaCo-2Bbe epithelial cellresistance in the presence of LNnT, 2′FL, and 6′SL.

FIG. 21 is a graph showing Post-confluent CaCo-2Bbe epithelial cellresistance in the presence of LNnT, 2′FL, and 6′SL.

FIG. 22 is a graph showing Post-confluent CaCo-2Bbe epithelial cellresistance in the presence of LNnT, 2′FL, and 6′SL.

FIG. 23A is a chart depicting the effect of human milk oligosaccharidesand dose dependency thereof on the expression of MUC2 as measured inExample 39.

FIG. 23B is a chart depicting the effect of human milk oligosaccharidesand dose dependency thereof on the expression of TFF3 as measured inExample 39.

FIG. 23C is a chart depicting the effect of human milk oligosaccharidesand dose dependency thereof on the expression of RELMβ as measured inExample 39.

FIG. 23D is a chart depicting the effect of human milk oligosaccharidesand dose dependency thereof on the expression of CHST5 as measured inExample 39.

FIG. 23E is a chart depicting the effect of human milk oligosaccharidesand dose dependency thereof on the expression of GAL3ST2 as measured inExample 39.

DETAILED DESCRIPTION OF THE DISCLOSURE

The nutritional compositions and methods described herein utilize HMOsalone or in combination with at least one other prebioticoligosaccharide and/or a probiotic for controlling and reducing a numberof diseases, disorders and conditions related to the gut-brain-immunesystem. These and other features of the nutritional compositions andmethods, as well as some of the many optional variations and additions,are described in detail hereafter.

The terms “retort packaging” and “retort sterilizing” are usedinterchangeably herein, and unless otherwise specified, refer to thecommon practice of filling a container, most typically a metal can orother similar package, with a nutritional liquid and then subjecting theliquid-filled package to the necessary heat sterilization step, to forma sterilized, retort packaged, nutritional liquid product.

The term “aseptic packaging” as used herein, unless otherwise specified,refers to the manufacture of a packaged product without reliance uponthe above-described retort packaging step, wherein the nutritionalliquid and package are sterilized separately prior to filling, and thenare combined under sterilized or aseptic processing conditions to form asterilized, aseptically packaged, nutritional liquid product.

The terms “fat” and “oil” as used herein, unless otherwise specified,are used interchangeably to refer to lipid materials derived orprocessed from plants or animals. These terms also include syntheticlipid materials so long as such synthetic materials are suitable fororal administration to humans.

The term “human milk oligosaccharide” or “HMO”, unless otherwisespecified, refers generally to a number of complex carbohydrates foundin human breast milk that can be in acidic or neutral form, and toprecursors thereof. Exemplary non-limiting human milk oligosaccharidesinclude 3′-sialyllactose, 6′-sialyllactose, 3′-fueosyllactose,2′-fueosyllactose, and lacto-N-neo-tetraose. Exemplary human milkoligosaccharide precursors includes sialic acid and/or fucose.

The term “shelf stable” as used herein, unless otherwise specified,refers to a nutritional product that remains commercially stable afterbeing packaged and then stored at 18-24° C. for at least 3 months,including from about 6 months to about 24 months, and also includingfrom about 12 months to about 18 months.

The terms “nutritional formulation” or “nutritional composition” as usedherein, are used interchangeably and, unless otherwise specified, referto synthetic formulas including nutritional liquids, nutritionalpowders, nutritional solids, nutritional semi-solids, nutritionalsemi-liquids, nutritional supplements, and any other nutritional foodproduct as known in the art. The nutritional powders may bereconstituted to form a nutritional liquid, all of which comprise one ormore of fat, protein and carbohydrate and are suitable for oralconsumption by a human. The terms “nutritional formulation” or“nutritional composition” do not include human breast milk.

The term “nutritional liquid” as used herein, unless otherwisespecified, refers to nutritional compositions in ready-to-drink liquidform, concentrated form, and nutritional liquids made by reconstitutingthe nutritional powders described herein prior to use.

The term “nutritional powder” as used herein, unless otherwisespecified, refers to nutritional compositions in flowable or scoopableform that can be reconstituted with water or another aqueous liquidprior to consumption and includes both spraydried anddrymixed/dryblended powders.

The term “nutritional semi-solid,” as used herein, unless otherwisespecified, refers to nutritional products that are intermediate inproperties, such as rigidity, between solids and liquids. Somesemi-solids examples include puddings, gelatins, and doughs.

The term “nutritional semi-liquid,” as used herein, unless otherwisespecified, refers to nutritional products that are intermediate inproperties, such as flow properties, between liquids and solids. Somesemi-liquids examples include thick shakes and liquid gels.

The term “infant” as used herein, unless otherwise specified, refers toa person 12 months or younger. The term “preterm infant” as used herein,refers to a person born prior to 36 weeks of gestation.

The term “toddler” as used herein, unless otherwise specified, refers toa person greater than one year of age up to three years of age.

The term “child” as used herein, unless otherwise specified, refers to aperson greater than three years of age up to twelve years of age.

The term “newborn” as used herein, unless otherwise specified, refers toa person from birth up to four weeks of age.

The terms “infant formula” or “synthetic infant formula” as used herein,unless otherwise specified, are used interchangeably and refer toliquid, semiliquid, solid, and semi-solid human milk replacements orsubstitutes that are suitable for consumption by an infant. Thesynthetic formulas include components that are of semi-purified orpurified origin. As used herein, unless otherwise specified, the terms“semi-purified” or “purified” refer to a material that has been preparedby purification of a natural material or by synthesis. The terms “infantformula” or “synthetic infant formula” do not include human breast milk.

The term “synthetic pediatric formula” as used herein, unless otherwisespecified, refers to liquid, semi-liquid, solid, and semi-solid humanmilk replacements or substitutes that are suitable for consumption by aninfant or toddler up to the age of 36 months (3 years). The syntheticformulas include components that are of semi-purified or purifiedorigin. As used herein, unless otherwise specified, the terms“semi-purified” or “purified” refer to a material that has been preparedby purification of a natural material or by synthesis. The term“synthetic pediatric nutritional formula” does not include human breastmilk.

The term “synthetic child formula” as used herein, unless otherwisespecified, refers to liquid, semi-liquid, solid, and semi-solid humanmilk replacements or substitutes that are suitable for consumption by achild up to the age of 12 years. The synthetic formulas includecomponents that are of semi-purified or purified origin. As used herein,unless otherwise specified, the terms “semi-purified” or “purified”refer to a material that has been prepared by purification of a naturalmaterial or by synthesis. The term “synthetic child nutritional formula”does not include human breast milk.

The term “preterm infant formula” as used herein, unless otherwisespecified, refers to liquid and solid nutritional products suitable forconsumption by a preterm infant.

The term “human milk fortifier” as used herein, unless otherwisespecified, refers to liquid and solid nutritional products suitable formixing with breast milk or preterm infant formula or infant formula forconsumption by a preterm or term infant.

The terms “susceptible” and “at risk” as used herein, unless otherwisespecified, mean having little resistance to a certain condition ordisease, including being genetically predisposed, having a familyhistory of, and/or having symptoms of the condition or disease.

The term “cognition” as used herein, unless otherwise specified, refersto an individual's ability for learning, memory acquisition, and memoryrecall.

The terms “growth of a virus” or “growth of bacteria” as used herein,unless otherwise specified, refer to the production, proliferation, orreplication of a virus or bacteria.

All percentages, parts and ratios as used herein, are by weight of thetotal composition, unless otherwise specified. All such weights, as theypertain to listed ingredients, are based on the active level and,therefore, do not include solvents or by-products that may be includedin commercially available materials, unless otherwise specified.

Numerical ranges as used herein are intended to include every number andsubset of numbers within that range, whether specifically disclosed ornot. Further, these numerical ranges should be construed as providingsupport for a claim directed to any number or subset of numbers in thatrange. For example, a disclosure of from 1 to 10 should be construed assupporting a range of from 2 to 8, from 3 to 7, from 5 to 6, from 1 to9, from 3.6 to 4.6, from 3.5 to 9.9, and so forth.

All references to singular characteristics or limitations of the presentdisclosure shall include the corresponding plural characteristic orlimitation, and vice versa, unless otherwise specified or clearlyimplied to the contrary by the context in which the reference is made.

All combinations of method or process steps as used herein can beperformed in any order, unless otherwise specified or clearly implied tothe contrary by the context in which the referenced combination is made.

The nutritional compositions and methods may comprise, consist of, orconsist essentially of the essential elements of the compositions andmethods as described herein, as well as any additional or optionalelement described herein or otherwise useful in nutritional compositionapplications.

Product Form

The nutritional compositions of the present disclosure may be formulatedand administered in any known or otherwise suitable oral product form.Any solid, semi-solid, liquid, semi-liquid, or powder product form,including combinations or variations thereof, are suitable for useherein, provided that such forms allow for safe and effective oraldelivery to the individual of the essential ingredients and any optionalingredients, as also defined herein.

The nutritional compositions of the present disclosure are desirablyformulated as dietary product forms, which are defined herein as thoseembodiments comprising the ingredients of the present disclosure in aproduct form that then contains at least one of fat, protein, andcarbohydrate, and preferably also contains vitamins, minerals, orcombinations thereof. The nutritional compositions will comprise atleast one HMO, and many times at least two or more HMOs, desirably incombination with at least one of protein, fat, vitamins, and minerals,to produce a nutritional combination.

The nutritional composition may be formulated with sufficient kinds andamounts of nutrients to provide a sole, primary, or supplemental sourceof nutrition, or to provide a specialized nutritional composition foruse in individuals afflicted with specific diseases, disorders, orconditions or with a targeted nutritional benefit as described below.

Specific non-limiting examples of product forms suitable for use withthe HMO-containing compositions as disclosed herein include, forexample, liquid and powdered dietary supplements, liquid and powderedhuman milk fortifiers, liquid and powdered preterm infant formulas,liquid and powdered infant formulas, liquid and powdered elemental andsemi-elemental formulas, liquid and powdered pediatric formulas, liquidand powdered toddler formulas, liquid and powdered follow-on formulas,liquid, powdered and solid adult nutritional formulas suitable for usewith individuals suffering from food intolerance, allergies, immunedisorders, and other gastrointestinal diseases, conditions, and/ordisorders.

Nutritional Liquids

Nutritional liquids include both concentrated and ready-to-feednutritional liquids. These nutritional liquids are most typicallyformulated as suspensions or emulsions, although other liquid forms arewithin the scope of the present disclosure.

Nutritional emulsions suitable for use may be aqueous emulsionscomprising proteins, fats, and carbohydrates. These emulsions aregenerally flowable or drinkable liquids at from about 1° C. to about 25°C. and are typically in the form of oil-in-water, water-in-oil, orcomplex aqueous emulsions, although such emulsions are most typically inthe form of oil-in-water emulsions having a continuous aqueous phase anda discontinuous oil phase.

The nutritional emulsions may be and typically are shelf stable. Thenutritional emulsions typically contain up to about 95% by weight ofwater, including from about 50% to about 95%, also including from about60% to about 90%, and also including from about 70% to about 85%, byweight of water. The nutritional emulsions may have a variety of productdensities, but most typically have a density greater than about 1.03g/mL, including greater than about 1.04 g/mL, including greater thanabout 1.055 g/mL, including from about 1.06 g/mL to about 1.12 g/mL, andalso including from about 1.085 g/mL to about 1.10 g/mL.

The nutritional emulsions may have a caloric density tailored to thenutritional needs of the ultimate user, although in most instances theemulsions comprise generally at least 19 kcal/fl oz (660 kcal/liter),more typically from about 20 kcal/fl oz (675-680 kcal/liter) to about 25kcal/fl oz (820 kcal/liter), even more typically from about 20 kcal/floz (675-680 kcal/liter) to about 24 kcal/fl oz (800-810 kcal/liter).Generally, the 22-24 kcal/fl oz formulas are more commonly used inpreterm or low birth weight infants, and the 20-21 kcal/fl oz (675-680to 700 kcal/liter) formulas are more often used in term infants. In someembodiments, the emulsion may have a caloric density of from about50-100 kcal/liter to about 660 kcal/liter, including from about 150kcal/liter to about 500 kcal/liter. In some specific embodiments, theemulsion may have a caloric density of 25, or 50, or 75, or 100kcal/liter.

The nutritional emulsion may have a pH ranging from about 3.5 to about8, but are most advantageously in a range of from about 4.5 to about7.5, including from about 5.5 to about 7.3, including from about 6.2 toabout 7.2.

Although the serving size for the nutritional emulsion can varydepending upon a number of variables, a typical serving size isgenerally at least about 1 mL, or even at least about 2 mL, or even atleast about 5 mL, or even at least about 10 mL, or even at least about25 mL, including ranges from about 2 mL toabout 300 mL, including fromabout 4 mL to about 250 mL, and including from about 10 mL to about 240mL.

Nutritional Solids

The nutritional solids may be in any solid form, but are typically inthe form of flowable or substantially flowable particulate compositions,or at least particulate compositions. Particularly suitable nutritionalsolid product forms include spray dried, agglomerated and/or dryblendedpowder compositions. The compositions can easily be scooped and measuredwith a spoon or similar other device, and can easily be reconstituted bythe intended user with a suitable aqueous liquid, typically water, toform a nutritional composition for immediate oral or enteral use. Inthis context, “immediate” use generally means within about 48 hours,most typically within about 24 hours, preferably right afterreconstitution.

The nutritional powders may be reconstituted with water prior to use toa caloric density tailored to the nutritional needs of the ultimateuser, although in most instances the powders are reconstituted withwater to form compositions comprising at least 19 kcal/fl oz (660kcal/liter), more typically from about 20 kcal/fl oz (675-680kcal/liter) to about 25 kcal/fl oz (820 kcal/liter), even more typicallyfrom about 20 kcal/fl oz (675-680 kcal/liter) to about 24 kcal/fl oz(800-810 kcal/liter). Generally, the 22-24 kcal/fl oz formulas are morecommonly used in preterm or low birth weight infants, and the 20-21kcal/fl oz (675-680 to 700 kcal/liter) formulas are more often used interm infants. In some embodiments, the reconstituted powder may have acaloric density of from about 50-100 kcal/liter to about 660 kcal/liter,including from about 150 kcal/liter to about 500 kcal/liter. In somespecific embodiments, the emulsion may have a caloric density of 25, or50, or 75, or 100 kcal/liter.

Human Milk Oligosaccharides (HMOs)

The nutritional compositions of the present disclosure include at leastone HMO, and in many embodiments, a combination of two or more HMOs.Oligosaccharides are one of the main components of human breast milk,which contains, on average, 10 grams per liter of neutraloligosaccharides and 1 gram perliter of acidic oligosaccharides. Thecompositional structure of HMOs is very complex and more than 200different oligosaccharide-like structures are known.

The HMO or HMOs may be included in the nutritional compositions alone,or in some embodiments, in combination with other components (e.g.,prebiotic oligosaccharides, probiotics, etc.) as described herein. Inmany embodiments, HMOs are included in the nutritional compositions withmultiple additional components. The HMO or HMOs may be isolated orenriched from milk(s) secreted by mammals including, but not limited to:human, bovine, ovine, porcine, or caprine species. The HMOs may also beproduced via microbial fermentation, enzymatic processes, chemicalsynthesis, or combinations thereof.

Suitable HMOs for use in the nutritional compositions may includeneutral oligosaccharides, acidic oligosaccharides, n-acetylglucosylatedoligosaccharides, and HMO precursors. Specific non-limiting examples ofHMOs that may be included individually or in combination in thecompositions of the present disclosure include: sialic acid (i.e., freesialic acid, lipid-bound sialic acid, protein-bound sialic acid);D-glucose (Glc); D-galactose (Gal); N-acetylglucosamine (GleNAc);L-fucose (Fuc); fucosyl oligosaccharides (i.e., Lacto-N-fucopentaose I;Lacto-N-fucopentaose II; 2′-Fucosyllactose; 3′-Fucosyllactose;Lacto-N-fucopentaose III; Lacto-N-difucohexaose I; andLactodifucotetraose); non-fucosylated, non-sialylated oligosaccharides(i.e., Lacto-N-tetraose and Lacto-N-neotetraose); sialyloligosaccharides (i.e., 3′-Sialyl-3-fucosyllactose;Disialomonofucosyllacto-N-neohexaose;Monofucosylmonosialyllacto-N-octaose (sialyl Lea);Sialyllacto-N-fucohexaose II; Disialyllacto-N-fucopentaose II;Monofucosyldisialyllacto-N-tetraose); and sialyl fucosyloligosaccharides (i.e., 2′-Sialyllactose; 2-Sialyllactosamine;3′-Sialyllactose; 3′-Sialyllactosamine; 6′-Sialyllactose;6′-Sialyllactosamine; Sialyllacto-N-neotetraose c;Monosialyllacto-N-hexaose; Disialyllacto-N-hexaose I;Monosialyllacto-N-neohexaose I; Monosialyllacto-N-neohexaose II;Disialyllacto-N-neohexaose; Disialyllacto-N-tetraose;Disialyllacto-N-hexaose II; Sialyllacto-N-tetraose a;Disialyllacto-N-hexaose I; and Sialyllacto-N-tetraose b). Also usefulare variants in which the glucose (Glc) at the reducing end is replacedby N-acetylglucosamine (e.g., 2′-fucosyl-N-acetylglucosamine (2′-FLNac)is such a variant to 2′-fucosyllactose). These HMOs are described morefully in U.S. Patent Application No. 2009/0098240, which is hereinincorporated by reference in its entirety. Other suitable examples ofHMOs that may be included in the compositions of the present disclosureinclude lacto-N-fucopentaose V, lacto-N-hexaose, para-lacto-N-hexaose,lacto-N-neohexaose, para-lacto-N-neohexaose, monofucosyllacto-N-hexaoseII, isomeric fucosylated lacto-N-hexaose (1), isomeric fucosylatedlacto-N-hexaose (3), isomeric fucosylated lacto-N-hexaose (2),difucosyl-para-lacto-N-neohexaose, difucosyl-para-lacto-N-hexaose,difucosyllacto-N-hexaose, lacto-N-neoocataose, para-lacto-N-octanose,iso-lacto-N-octaose, lacto-N-octaose, monofucosyllacto-neoocataose,monofucosyllacto-N-ocataose, difucosyllacto-N-octaose I,difucosyllacto-N-octaose II, difucosyllacto-N-neoocataose II,difucosyllacto-N-neoocataose I, lacto-N-decaose,trifucosyllacto-N-neooctaose, trifucosyllacto-N-octaose,trifucosyl-iso-lacto-N-octaose, lacto-N-difuco-hexaose II,sialyl-lacto-N-tetraose a, sialyl-lacto-N-tetraose b,sialyl-lacto-N-tetraose c, sialyl-fucosyl-lacto-N-tetraose I,sialyl-fucosyl-lacto-N-tetraose II, and disialyl-lacto-N-tetraose, andcombinations thereof Particularly suitable nutritional compositionsinclude at least one of the following HMOs or HMO precursors: sialicacid (SA); 2′-Sialyllactose (2′SL); 3′-Sialyllactose (3′SL);6′-Sialyllactose (6′SL); 2′-Fucosyllactose (2′FL); 3′-Fucosyllactose(3′FL); and Lacto-N-tetraose and Lacto-N-neotetraose (LNnT), and inparticular, combinations of 2′FL with at least one of 6′SL and 3′SL; andcombinations of LNnT with at least one of 6′SL and 3′FL.

Other exemplary combinations include: SA, 3′SL, 6′SL, 3′FL, 2′FL, andLNnT; 3′SL, 6′SL, 3′FL, 2′FL, and LNnT; SA, 6′SL, 3′FL, 2′FL, and LNnT;SA, 3′SL, 3′FL, 2′FL, and LNnT; SA, 3′SL, 6′SL, 2′FL, and LNnT; SA,3′SL, 6′SL, 3′FL, and LNnT; SA, 3′SL, 6′SL, 3′FL, and 2′FL; SA and 3′SL;SA and 6′SL; SA and 2′FL; SA and LNnT; SA, 3′SL, and 6′SL; SA, 3′SL and3′FL; SA, 3′SL and 2′FL; SA, 3′SL and LNnT; SA, 6′SL and 3′FL; SA, 6′SL,and 2′FL; SA, 6′SL, and LNnT; SA, 3′FL, and 2′FL; SA, 3′FL, and LNnT;SA, 2′FL, and LNnT; SA, 3′SL, 6′SL, and 3′FL; SA, 3′SL, 6′SL and 2′FL;SA, 3′SL, 6′SL, and LNnT; SA, 3′SL, 3′FL, and 2′FL; SA, 3′SL, 3′FL, andLNnT; SA, 3′SL, 2′FL, and LNnT; SA, 6′SL, 3′FL, and 2′FL; SA, 6′SL,2′FL, and LNnT; SA, 6′SL, 3′FL, and LNnT; SA, 3′FL, 2′FL, and LNnT; SA,6′SL, 2′FL, and LNnT; SA, 3′SL, 3′FL, 2′FL, and LNnT; SA, 6′SL, 3′FL,2′FL, and LNnT; SA, 3′SL, 6′SL, 3′FL, and LNnT; SA, 3′SL, 3′FL, 2′FL,and LNnT; SA, 3′SL, 6′SL, 2′FL, and LNnT; 3′SL, 6′SL, 3′FL, and 2′FL;3′SL, 6′SL, 2′FL, and LNnT; 3′SL, 3′FL, 2′FL, and LNnT; 3′SL, 6′SL,3′FL, and LNnT; 3′SL, 6′SL, and 3′FL; 3′SL, 3′FL, and 2′FL; 3′SL, 2′FL,and LNnT; 3′SL, 6′SL, and 2′FL; 3′SL, 6′SL, and LNnT; 3′SL and 3′FL;3′SL and 2′FL; 3′SL and LNnT; 6′SL and 3′FL; 6′SL and 2′FL; 6′SL andLNnT; 6′SL, 3′FL, and LNnT; 6′SL, 3′FL, 2′FL, and LNnT; 3′FL, 2′FL, andLNnT; 3′FL and LNnT; and 2′FL and LNnT.

The HMOs are present in the nutritional compositions in total amounts ofHMO in the composition (mg of HMO per mL of composition) of at leastabout 0.001 mg/mL, including at least about 0.01 mg/mL, including fromabout 0.001 mg/mL to about 20 mg/mL, including from about 0.01 mg/mL toabout 20 mg/mL, including from about 0.001 mg/mL to about 15 mg/mL,including from about 0.01 mg/mL to about 15 mg/mL, including from about0.001 mg/mL to about 10 mg/mL, including from about 0.01 mg/mL to about10 mg/mL, including from about 0.001 mg/mL to about 5 mg/mL, includingfrom about 0.01 mg/mL to about 5 mg/mL, and including from about 0.001mg/mL to about 1 mg/mL of total HMO in the nutritional composition,including from about 0.001 mg/mL to about 0.23 mg/mL, and including fromabout 0.01 mg/mL to about 0.23 mg/mL. Typically, the amount of HMO inthe nutritional composition will depend on the specific HMO or HMOspresent and the amounts of other components in the nutritionalcompositions.

In one specific embodiment when the nutritional composition is anutritional powder, the total concentration of HMOs in the nutritionalpowder is from about 0.0005% to about 5%, including from about 0.01% toabout 1% (by weight of the nutritional powder).

In another specific embodiment, when the nutritional composition is aready-to-feed nutritional liquid, the total concentration of HMOs in theready-to-feed nutritional liquid is from about 0.0001% to about 0.50%,including from about 0.001% to about 0.15%, including from about 0.01%to about 0.10%, and further including from about 0.01% to about 0.03%(by weight of the ready-to-feed nutritional liquid).

In another specific embodiment, when the nutritional composition is aconcentrated nutritional liquid, the total concentration of HMOs in theconcentrated liquid is from about 0.0002% to about 0.60%, including fromabout 0.002% to about 0.30%, including from about 0.02% to about 0.20%,and further including from about 0.02% to about 0.06% (by weight of theconcentrated nutritional liquid).

In one specific embodiment, the nutritional composition includes aneutral human milk oligosaccharide in an amount of from about 0.001mg/mL to about 20 mg/mL, including from 0.01 mg/mL to about 20 mg/mL,including from about 0.001 mg/mL to less than 2 mg/mL, and includingfrom about 0.01 mg/mL to less than 2 mg/mL.

In one specific embodiment of the present disclosure, a nutritionalcomposition includes 2′FL. The 2′FL may be the only HMO included in thenutritional composition, or other additional HMOs may also be includedin the nutritional composition (e.g., the 2′FL may be combined with 3′SLand/or 6′SL in some specific embodiments). In one embodiment, the 2′FLis included in the nutritional composition in an amount of from about0.001 mg/mL to about 20 mg/mL, including from about 0.01 mg/mL to about20 mg/mL, including from about 0.001 mg/mL to less than 2 mg/mL, andincluding from about 0.01 mg/mL to less than 2 mg/mL. In anotherembodiment, the 2′FL is included in the nutritional composition in anamount of from about 0.001 mg/mL to about 20 mg/mL, including from about0.01 mg/mL to about 20 mg/mL, including from greater than 2.5 mg/mL toabout 20 mg/mL, including from greater than 2.5 mg/mL to about 15 mg/mL,and including from greater than 2.5 mg/mL to about 10 mg/mL.

In one specific embodiment, the nutritional composition includes 6′SL,alone or in combination with other HMOs, in an amount of from about0.001 mg/mL to about 20 mg/mL, including from about 0.01 mg/mL to about20 mg/mL, including from about 0.001 mg/mL to less than 0.25 mg/mL, andincluding from about 0.01 mg/mL to less than 0.25 mg/mL. In anotherembodiment, the nutritional composition includes 6′SL, alone or incombination with other HMOs, in an amount of from about 0.001 mg/mL toabout 20 mg/mL, including from about 0.01 mg/mL to about 20 mg/mL,including from greater than 0.4 mg/mL to about 20 mg/mL, including fromgreater than 0.4 mg/mL to about 15 mg/mL, and including from greaterthan 0.4 mg/mL to about 10 mg/mL.

In one embodiment, when the nutritional composition includes 6′SL, thetotal amount of HMOs in the nutritional composition includes at leastabout 88% (by total weight HMOs) 6′SL, including from about 88% (bytotal weight HMOs) to about 96% (by total weight HMOs), including fromabout 88% (by total weight HMOs) to about 100% (by total weight HMOs),and including about 100% (by total weight HMOs) 6′SL.

In another embodiment, the nutritional composition includes 3′SL, aloneor in combination with other HMOs, in an amount of from about 0.001mg/mL to about 20 mg/mL, including from about 0.01 mg/mL to about 20mg/mL, including from about 0.001 mg/mL to less than 0.15 mg/mL,including from about 0.01 mg/mL to less than 0.15 mg/mL, including fromgreater than 0.25 mg/mL to about 20 mg/mL, including from greater than0.25 mg/mL to about 15 mg/mL, and including from greater than 0.25 mg/mLto about 10 mg/mL.

In one embodiment, when the nutritional composition includes 3′SL, thetotal amount of HMOs in the nutritional composition includes at leastabout 85% (by total weight HMOs) 3′SL, including from about 85% (bytotal weight HMOs) to about 88% (by total weight HMOs), including fromabout 88% (by total weight HMOs) to about 100% (by total weight HMOs),and including about 100% (by total weight HMOs) 3′SL.

In one specific embodiment, the nutritional composition includes LNnT,alone or in combination with other HMOs, in an amount of from about0.001 mg/mL to about 20 mg/mL, including from about 0.01 mg/mL to about20 mg/mL, including from about 0.001 mg/mL to less than 0.2 mg/mL,including from about 0.01 mg/mL to less than 0.2 mg/mL, including fromgreater than 0.32 mg/mL to about 20 mg/mL, including from greater than0.32 mg/mL to about 15 mg/mL, and including from greater than 0.32 mg/mLto about 10 mg/mL.

Additional Prebiotic Oligosaccharides

The nutritional compositions of the present disclosure may, in additionto the HMOs described above, comprise an additional source or sources ofprebiotic oligosaccharides (the total amount of oligosaccharides beingreferred to herein as an “oligosaccharide blend” of the nutritionalcomposition). Suitable additional sources of prebiotic oligosaccharidesfor use in the nutritional compositions include any prebioticoligosaccharide that is suitable for use in an oral nutritionalcomposition and is compatible with the essential elements and featuresof such compositions. In some embodiments, the nutritional compositionincludes a combination of one or more HMOs and one or more additionalprebiotic oligosaccharides such that the composition provides asynergistic benefit to the end user, such as a synergistic benefit inimproving feeding intolerance in infants.

In some embodiments, the combinations of HMO or HMOs with the additionalprebiotic oligosaccharides to provide the synergistic effect includeHMOs and additional prebiotic oligosaccharides that ferment at a rapidrate (“rapidly-fermenting oligosaccharides”), oligosaccharides thatferment at a moderate rate (“medium-fermenting oligosaccharides”),and/or oligosaccharides that ferment at a slow rate (“slowly-fermentingoligosaccharides”). Some preferred embodiments provide a nutritionalcomposition that includes at least one HMO in combination with arapidly-fermenting oligosaccharide, a medium-fermenting oligosaccharide,and/or a slowly-fermenting oligosaccharide.

Non-limiting examples of suitable additional prebiotic oligosaccharidesfor use in the nutritional compositions described herein includeprebiotic oligosaccharides that have a degree of polymerization (DP) ofat least 2 monose units, which are not or only partially digested in theintestine by the action of acids or digestive enzymes present in thehuman upper digestive tract (small intestine and stomach), but which arefermentable by the human intestinal flora. The term “monose units”refers to units having a closed ring structure, preferably hexose, e.g.,the pyranose or furanose forms. Particularly preferred oligosaccharidesfor use in combination with the HMO or HMOs in the nutritionalcompositions of the present disclosure include galactooligosaccharides(GOS), fructooligosaccharides (FOS), short chain fructooligosaccharides,inulin, polydextrose (PDX), pectin hydrolysate, and gum fiber. In onespecific embodiment, the gum fiber is gum arabic.

The oligosaccharide blend is present in the nutritional compositions ina total amount of at least about 0.001 mg/mL, including at least about0.01 mg/mL, including at least about 0.1 mg/mL, including at least about1 mg/mL, including from about 0.001 mg/mL to about 20 mg/mL, includingfrom about 1 mg/mL to about 20 mg/mL, including from about 1 mg/mL toabout 15 mg/mL, including from about 1 mg/mL to about 10 mg/mL,including from about 1 mg/mL to about 5 mg/mL, and including from about2 mg/mL to about 20 mg/mL. In one embodiment, the oligosaccharide blendis present in the nutritional composition in a total amount of fromabout 1 mg/mL to about 4 mg/mL.

Typically, when used as an oligosaccharide blend, the nutritionalcompositions, in addition to the HMO or HMOs, include at least onerapidly-fermented oligosaccharide, at least one medium-fermentedoligosaccharide, and, optionally, at least one slowly-fermentedoligosaccharide to provide a nutritional composition that is toleratedwell by preterm and term infants (i.e., reduced gassiness and/or stoolfrequency). Rapidly-fermented oligosaccharides generally have afermentation rate of greater than 4,000 i.tg/g of dry matter/hour;medium-fermented oligosaccharides generally have a fermentation rate offrom 1,500 i.tg/g of dry matter/hour to 4,000 i.tg/g of dry matter/hour;and slowly-fermented oligosaccharides generally have a fermentation rateof less than 1,500 i.tg/g of dry matter/hour.

By way of specific example, rapidly-fermented oligosaccharides includeFOS, GOS (about 9,304 i.tg/g of dry matter/hour), LNnT (about 4,488i.tg/g of dry matter/hour), 2′FL (about 4,872 i.tg/g of drymatter/hour), and combinations thereof. Medium-fermentedoligosaccharides include 6′SL (about 1,809 i.tg/g of dry matter/hour),3′SL, 2′FL, 3′FL, LNnT and combinations thereof. Slowly-fermentedoligosaccharides include longer chain carbohydrates such as inulin(about 1,435 i.tg/g of dry matter/hour), gum fibers (e.g., gum arabic(about 785 i.tg/g of dry matter/hour)), and combinations thereof

When used in an oligosaccharide blend, the rapidly-fermentedoligosaccharides can be included in the nutritional compositions inamounts of from about 0.05 mg/mL to about 20 mg/mL, including from about0.5 mg/mL to about 15 mg/mL, including from about 0.5 mg/mL to about 10mg/mL, including from about 1 mg/mL to about 15 mg/mL, including fromabout 1 mg/mL to about 10 mg/mL, including from about 2 mg/mL to about 8mg/mL, and also including from about 3 mg/mL to about 5 mg/mL. Themedium-fermented oligosaccharides can be included in the nutritionalcompositions in amounts of from about 0.05 mg/mL to about 20 mg/mL,including from about 0.05 mg/mL to about 15 mg/mL, including from about0.05 mg/mL to about 10 mg/mL, including from about 0.05 mg/mL to about 5mg/mL, including from about 0.05 mg/mL to about 2.5 mg/mL, includingfrom about 0.05 mg/mL to about 1 mg/mL, including from about 0.05 mg/mLto about 0.5 mg/mL, and including from about 0.05 mg/mL to about 0.25mg/mL. The slowly-fermented oligosaccharides can be included in thenutritional compositions in amounts of from about 0.05 mg/mL to about 20mg/mL, including from about 0.05 mg/mL to about 15 mg/mL, including fromabout 0.05 mg/mL to about 10 mg/mL, including from about 0.05 mg/mL toabout 5 mg/mL, and also including from about 0.05 mg/mL to about 2.5mg/mL.

In one specific embodiment, the nutritional composition includes anoligosaccharide blend including LNnT, 6′SL and inulin in a total amountof oligosaccharide blend of from about 0.05 mg/mL to about 20 mg/mL.

In another specific embodiment, the nutritional composition includes anoligosaccharide blend including 2′FL, 6′SL and inulin in a total amountof oligosaccharide blend of from about 0.001 mg/mL to about 20 mg/mL,including from about 0.01 mg/mL to about 20 mg/mL.

Other exemplary combinations include: FOS, GOS, 2′FL, LNnT, 3′SL, and6′SL; FOS, GOS, 2′FL, 3′SL, and 6′SL; FOS, GOS, LNnT, 3′SL, and 6′SL;FOS, 2′FL, LNnT, 3′SL, and 6′SL; GOS, 2′FL, LNnT, 3′SL, and 6′SL; FOS,GOS, 3′SL, and 6′SL; FOS, 2′FL, 3′SL, and 6′SL; FOS, LNnT, 3′SL, and6′SL; GOS, 2′FL, 3′SL, and 6′SL; GOS, LNnT, 3′SL, and 6′SL; 2′FL, LNnT,3′SL, and 6′SL; FOS, 3′SL, and 6′SL; GOS, 3′SL, and 6′SL; 2′FL, 3′SL,and 6′SL; LNnT, 3′SL, and 6′SL; FOS, GOS, 2′FL, LNnT, and 3′SL; FOS,GOS, 2′FL, and 3′SL; FOS, GOS, LNnT, and 3′SL; FOS, 2′FL, LNnT, and3′SL; GOS, 2′FL, LNnT, and 3′SL; FOS, GOS, and 3′SL; FOS, 2′FL, and3′SL; FOS, LNnT, and 3′SL; GOS, 2′FL, and 3′SL; GOS, LNnT, and 3′SL;2′FL, LNnT, and 3′SL; FOS and 3′SL; GOS and 3′SL; 2′FL and 3′SL; LNnTand 3′SL; FOS, GOS, 2′FL, LNnT, and 6′SL; FOS, GOS, 2′FL, and 6′SL; FOS,GOS, LNnT, and 6′SL; FOS, 2′FL, LNnT, and 6′SL; GOS, 2′FL, LNnT, and6′SL; FOS, GOS, and 6′SL; FOS, 2′FL, and 6′SL; FOS, LNnT, and 6′SL; GOS,2′FL, and 6′SL; GOS, LNnT, and 6′SL; 2′FL, LNnT, and 6′SL; FOS and 6′SL;GOS and 6′SL; 2′FL and 6′SL; and LNnT and 6′SL.

Further exemplary combinations include: FOS, GOS, 2′FL, LNnT, 3′SL,6′SL, inulin, a gum, and polydextrose; FOS, GOS, 2′FL, 3′SL, 6′SL,inulin, a gum, and polydextrose; FOS, GOS, LNnT, 3′SL, 6′SL, inulin, agum, and polydextrose; FOS, 2′FL, LNnT, 3′SL, 6′SL, inulin, a gum, andpolydextrose; GOS, 2′FL, LNnT, 3′SL, 6′SL, inulin, a gum, andpolydextrose; FOS, GOS, 3′SL, 6′SL, inulin, a gum, and polydextrose;FOS, 2′FL, 3′SL, 6′SL, inulin, a gum, and polydextrose; FOS, LNnT, 3′SL,6′SL, inulin, a gum, and polydextrose; GOS, 2′FL, 3′SL, 6′SL, inulin, agum, and polydextrose; GOS, LNnT, 3′SL, 6′SL, inulin, a gum, andpolydextrose; 2′FL, LNnT, 3′SL, 6′SL, inulin, a gum, and polydextrose;FOS, 3′SL, 6′SL, inulin, a gum, and polydextrose; GOS, 3′SL, 6′SL,inulin, a gum, and polydextrose; 2′FL, 3′SL, 6′SL, inulin, a gum, andpolydextrose; LNnT, 3′SL, 6′SL, inulin, a gum, and polydextrose; FOS,GOS, 2′FL, LNnT, 3′SL, inulin, a gum, and polydextrose; FOS, GOS, 2′FL,3′SL, inulin, a gum, and polydextrose; FOS, GOS, LNnT, 3′SL, inulin, agum, and polydextrose; FOS, 2′FL, LNnT, 3′SL, inulin, a gum, andpolydextrose; GOS, 2′FL, LNnT, 3′SL, inulin, a gum, and polydextrose;FOS, GOS, 3′SL, inulin, a gum, and polydextrose; FOS, 2′FL, 3′SL,inulin, a gum, and polydextrose; FOS, LNnT, 3′SL, inulin, a gum, andpolydextrose; GOS, 2′FL, 3′SL, inulin, a gum, and polydextrose; GOS,LNnT, 3′SL, inulin, a gum, and polydextrose; 2′FL, LNnT, 3′SL, inulin, agum, and polydextrose; FOS, 3′SL, inulin, a gum, and polydextrose; GOS,3′SL, inulin, a gum, and polydextrose; 2′FL, 3′SL, inulin, a gum, andpolydextrose; LNnT, 3′SL, inulin, a gum, and polydextrose; FOS, GOS,2′FL, LNnT, 6′SL, inulin, a gum, and polydextrose; FOS, GOS, 2′FL, 6′SL,inulin, a gum, and polydextrose; FOS, GOS, LNnT, 6′SL, inulin, a gum,and polydextrose; FOS, 2′FL, LNnT, 6′SL, inulin, a gum, andpolydextrose; GOS, 2′FL, LNnT, 6′SL, inulin, a gum, and polydextrose;FOS, GOS, 6′SL, inulin, a gum, and polydextrose; FOS, 2′FL, 6′SL,inulin, a gum, and polydextrose; FOS, LNnT, 6′SL, inulin, a gum, andpolydextrose; GOS, 2′FL, 6′SL, inulin, a gum, and polydextrose; GOS,LNnT, 6′SL, inulin, a gum, and polydextrose; 2′FL, LNnT, 6′SL, inulin, agum, and polydextrose; FOS, 6′SL, inulin, a gum, and polydextrose; GOS,6′SL, inulin, a gum, and polydextrose; 2′FL, 6′SL, inulin, a gum, andpolydextrose; LNnT, 6′SL, inulin, a gum, and polydextrose; FOS, GOS,2′FL, LNnT, 3′SL, 6′SL, inulin, and a gum; FOS, GOS, 2′FL, 3′SL, 6′SL,inulin, and a gum; FOS, GOS, LNnT, 3′SL, 6′SL, inulin, and a gum; FOS,2′FL, LNnT, 3′SL, 6′SL, inulin, and a gum; GOS, 2′FL, LNnT, 3′SL, 6′SL,inulin, and a gum; FOS, GOS, 3′SL, 6′SL, inulin, and a gum; FOS, 2′FL,3′SL, 6′SL, inulin, and a gum; FOS, LNnT, 3′SL, 6′SL, inulin, and a gum;GOS, 2′FL, 3′SL, 6′SL, inulin, and a gum; GOS, LNnT, 3′SL, 6′SL, inulin,and a gum; 2′FL, LNnT, 3′SL, 6′SL, inulin, and a gum; FOS, 3′SL, 6′SL,inulin, and a gum; GOS, 3′SL, 6′SL, inulin, and a gum; 2′FL, 3′SL, 6′SL,inulin, and a gum; LNnT, 3′SL, 6′SL, inulin, and a gum; FOS, GOS, 2′FL,LNnT, 3′SL, inulin, and a gum; FOS, GOS, 2′FL, 3′SL, inulin, and a gum;FOS, GOS, LNnT, 3′SL, inulin, and a gum; FOS, 2′FL, LNnT, 3′SL, inulin,and a gum; GOS, 2′FL, LNnT, 3′SL, inulin, and a gum; FOS, GOS, 3′SL,inulin, and a gum; FOS, 2′FL, 3′SL, inulin, and a gum; FOS, LNnT, 3′SL,inulin, and a gum; GOS, 2′FL, 3′SL, inulin, and a gum; GOS, LNnT, 3′SL,inulin, and a gum; 2′FL, LNnT, 3′SL, inulin, and a gum; FOS, 3′SL,inulin, and a gum; GOS, 3′SL, inulin, and a gum; 2′FL, 3′SL, inulin, anda gum; LNnT, 3′SL, inulin, and a gum; FOS, GOS, 2′FL, LNnT, 6′SL,inulin, and a gum; FOS, GOS, 2′FL, 6′SL, inulin, and a gum; FOS, GOS,LNnT, 6′SL, inulin, and a gum; FOS, 2′FL, LNnT, 6′SL, inulin, and a gum;GOS, 2′FL, LNnT, 6′SL, inulin, and a gum; FOS, GOS, 6′SL, inulin, and agum; FOS, 2′FL, 6′SL, inulin, and a gum; FOS, LNnT, 6′SL, inulin, and agum; GOS, 2′FL, 6′SL, inulin, and a gum; GOS, LNnT, 6′SL, inulin, and agum; 2′FL, LNnT, 6′SL, inulin, and a gum; FOS, 6′SL, inulin, and a gum;GOS, 6′SL, inulin, and a gum; 2′FL, 6′SL, inulin, and a gum; LNnT, 6′SL,inulin, and a gum; FOS, GOS, 2′FL, LNnT, 3′SL, 6′SL, inulin, andpolydextrose; FOS, GOS, 2′FL, 3′SL, 6′SL, inulin, and polydextrose; FOS,GOS, LNnT, 3′SL, 6′SL, inulin, and polydextrose; FOS, 2′FL, LNnT, 3′SL,6′SL, inulin, and polydextrose; GOS, 2′FL, LNnT, 3′SL, 6′SL, inulin, andpolydextrose; FOS, GOS, 3′SL, 6′SL, inulin, and polydextrose; FOS, 2′FL,3′SL, 6′SL, inulin, and polydextrose; FOS, LNnT, 3′SL, 6′SL, inulin, andpolydextrose; GOS, 2′FL, 3′SL, 6′SL, inulin, and polydextrose; GOS,LNnT, 3′SL, 6′SL, inulin, and polydextrose; 2′FL, LNnT, 3′SL, 6′SL,inulin, and polydextrose; FOS, 3′SL, 6′SL, inulin, and polydextrose;GOS, 3′SL, 6′SL, inulin, and polydextrose; 2′FL, 3′SL, 6′SL, inulin, andpolydextrose; LNnT, 3′SL, 6′SL, inulin, and polydextrose; FOS, GOS,2′FL, LNnT, 3′SL, inulin, and polydextrose; FOS, GOS, 2′FL, 3′SL,inulin, and polydextrose; FOS, GOS, LNnT, 3′SL, inulin, andpolydextrose; FOS, 2′FL, LNnT, 3′SL, inulin, and polydextrose; GOS,2′FL, LNnT, 3′SL, inulin, and polydextrose; FOS, GOS, 3′SL, inulin, andpolydextrose; FOS, 2′FL, 3′SL, inulin, and polydextrose; FOS, LNnT,3′SL, inulin, and polydextrose; GOS, 2′FL, 3′SL, inulin, andpolydextrose; GOS, LNnT, 3′SL, inulin, and polydextrose; 2′FL, LNnT,3′SL, inulin, and polydextrose; FOS, 3′SL, inulin, and polydextrose;GOS, 3′SL, inulin, and polydextrose; 2′FL, 3′SL, inulin, andpolydextrose; LNnT, 3′SL, inulin, and polydextrose; FOS, GOS, 2′FL,LNnT, 6′SL, inulin, and polydextrose; FOS, GOS, 2′FL, 6′SL, inulin, andpolydextrose; FOS, GOS, LNnT, 6′SL, inulin, and polydextrose; FOS, 2′FL,LNnT, 6′SL, inulin, and polydextrose; GOS, 2′FL, LNnT, 6′SL, inulin, andpolydextrose; FOS, GOS, 6′SL, inulin, and polydextrose; FOS, 2′FL, 6′SL,inulin, and polydextrose; FOS, LNnT, 6′SL, inulin, and polydextrose;GOS, 2′FL, 6′SL, inulin, and polydextrose; GOS, LNnT, 6′SL, inulin, andpolydextrose; 2′FL, LNnT, 6′SL, inulin, and polydextrose; FOS, 6′SL,inulin, and polydextrose; GOS, 6′SL, inulin, and polydextrose; 2′FL,6′SL, inulin, and polydextrose; LNnT, 6′SL, inulin, and polydextrose;FOS, GOS, 2′FL, LNnT, 3′SL, 6′SL, a gum, and polydextrose; FOS, GOS,2′FL, 3′SL, 6′SL, a gum, and polydextrose; FOS, GOS, LNnT, 3′SL, 6′SL, agum, and polydextrose; FOS, 2′FL, LNnT, 3′SL, 6′SL, a gum, andpolydextrose; GOS, 2′FL, LNnT, 3′SL, 6′SL, a gum, and polydextrose; FOS,GOS, 3′SL, 6′SL, a gum, and polydextrose; FOS, 2′FL, 3′SL, 6′SL, a gum,and polydextrose; FOS, LNnT, 3′SL, 6′SL, a gum, and polydextrose; GOS,2′FL, 3′SL, 6′SL, a gum, and polydextrose; GOS, LNnT, 3′SL, 6′SL, a gum,and polydextrose; 2′FL, LNnT, 3′SL, 6′SL, a gum, and polydextrose; FOS,3′SL, 6′SL, a gum, and polydextrose; GOS, 3′SL, 6′SL, a gum, andpolydextrose; 2′FL, 3′SL, 6′SL, a gum, and polydextrose; LNnT, 3′SL,6′SL, a gum, and polydextrose; FOS, GOS, 2′FL, LNnT, 3′SL, a gum, andpolydextrose; FOS, GOS, 2′FL, 3′SL, a gum, and polydextrose; FOS, GOS,LNnT, 3′SL, a gum, and polydextrose; FOS, 2′FL, LNnT, 3′SL, a gum, andpolydextrose; GOS, 2′FL, LNnT, 3′SL, a gum, and polydextrose; FOS, GOS,3′SL, a gum, and polydextrose; FOS, 2′FL, 3′SL, a gum, and polydextrose;FOS, LNnT, 3′SL, a gum, and polydextrose; GOS, 2′FL, 3′SL, a gum, andpolydextrose; GOS, LNnT, 3′SL, a gum, and polydextrose; 2′FL, LNnT,3′SL, a gum, and polydextrose; FOS, 3′SL, a gum, and polydextrose; GOS,3′SL, a gum, and polydextrose; 2′FL, 3′SL, a gum, and polydextrose;LNnT, 3′SL, a gum, and polydextrose; FOS, GOS, 2′FL, LNnT, 6′SL, a gum,and polydextrose; FOS, GOS, 2′FL, 6′SL, a gum, and polydextrose; FOS,GOS, LNnT, 6′SL, a gum, and polydextrose; FOS, 2′FL, LNnT, 6′SL, a gum,and polydextrose; GOS, 2′FL, LNnT, 6′SL, a gum, and polydextrose; FOS,GOS, 6′SL, a gum, and polydextrose; FOS, 2′FL, 6′SL, a gum, andpolydextrose; FOS, LNnT, 6′SL, a gum, and polydextrose; GOS, 2′FL, 6′SL,a gum, and polydextrose; GOS, LNnT, 6′SL, a gum, and polydextrose; 2′FL,LNnT, 6′SL, a gum, and polydextrose; FOS, 6′SL, a gum, and polydextrose;GOS, 6′SL, a gum, and polydextrose; 2′FL, 6′SL, a gum, and polydextrose;LNnT, 6′SL, a gum, and polydextrose; FOS, GOS, 2′FL, LNnT, 3′SL, 6′SL,and inulin; FOS, GOS, 2′FL, 3′SL, 6′SL, and inulin; FOS, GOS, LNnT,3′SL, 6′SL, and inulin; FOS, 2′FL, LNnT, 3′SL, 6′SL, and inulin; GOS,2′FL, LNnT, 3′SL, 6′SL, and inulin; FOS, GOS, 3′SL, 6′SL, and inulin;FOS, 2′FL, 3′SL, 6′SL, and inulin; FOS, LNnT, 3′SL, 6′SL, and inulin;GOS, 2′FL, 3′SL, 6′SL, and inulin; GOS, LNnT, 3′SL, 6′SL, and inulin;2′FL, LNnT, 3′SL, 6′SL, and inulin; FOS, 3′SL, 6′SL, and inulin; GOS,3′SL, 6′SL, and inulin; 2′FL, 3′SL, 6′SL, and inulin; LNnT, 3′SL, 6′SL,and inulin; FOS, GOS, 2′FL, LNnT, 3′SL, and inulin; FOS, GOS, 2′FL,3′SL, and inulin; FOS, GOS, LNnT, 3′SL, and inulin; FOS, 2′FL, LNnT,3′SL, and inulin; GOS, 2′FL, LNnT, 3′SL, and inulin; FOS, GOS, 3′SL, andinulin; FOS, 2′FL, 3′SL, and inulin; FOS, LNnT, 3′SL, and inulin; GOS,2′FL, 3′SL, and inulin; GOS, LNnT, 3′SL, and inulin; 2′FL, LNnT, 3′SL,and inulin; FOS, 3′SL, and inulin; GOS, 3′SL, and inulin; 2′FL, 3′SL,and inulin; LNnT, 3′SL, and inulin; FOS, GOS, 2′FL, LNnT, 6′SL, andinulin; FOS, GOS, 2′FL, 6′SL, and inulin; FOS, GOS, LNnT, 6′SL, andinulin; FOS, 2′FL, LNnT, 6′SL, and inulin; GOS, 2′FL, LNnT, 6′SL, andinulin; FOS, GOS, 6′SL, and inulin; FOS, 2′FL, 6′SL, and inulin; FOS,LNnT, 6′SL, and inulin; GOS, 2′FL, 6′SL, and inulin; GOS, LNnT, 6′SL,and inulin; 2′FL, LNnT, 6′SL, and inulin; FOS, 6′SL, and inulin; GOS,6′SL, and inulin; FOS, GOS, 2′FL, LNnT, 3′SL, 6′SL, and polydextrose;FOS, GOS, 2′FL, 3′SL, 6′SL, and polydextrose; FOS, GOS, LNnT, 3′SL,6′SL, and polydextrose; FOS, 2′FL, LNnT, 3′SL, 6′SL, and polydextrose;GOS, 2′FL, LNnT, 3′SL, 6′SL, and polydextrose; FOS, GOS, 3′SL, 6′SL, andpolydextrose; FOS, 2′FL, 3′SL, 6′SL, and polydextrose; FOS, LNnT, 3′SL,6′SL, and polydextrose; GOS, 2′FL, 3′SL, 6′SL, and polydextrose; GOS,LNnT, 3′SL, 6′SL, and polydextrose; 2′FL, LNnT, 3′SL, 6′SL, andpolydextrose; FOS, 3′SL, 6′SL, and polydextrose; GOS, 3′SL, 6′SL, andpolydextrose; 2′FL, 3′SL, 6′SL, and polydextrose; LNnT, 3′SL, 6′SL, andpolydextrose; FOS, GOS, 2′FL, LNnT, 3′SL, and polydextrose; FOS, GOS,2′FL, 3′SL, and polydextrose; FOS, GOS, LNnT, 3′SL, and polydextrose;FOS, 2′FL, LNnT, 3′SL, and polydextrose; GOS, 2′FL, LNnT, 3′SL, andpolydextrose; FOS, GOS, 3′SL, and polydextrose; FOS, 2′FL, 3′SL, andpolydextrose; FOS, LNnT, 3′SL, and polydextrose; GOS, 2′FL, 3′SL, andpolydextrose; GOS, LNnT, 3′SL, and polydextrose; 2′FL, LNnT, 3′SL, andpolydextrose; FOS, 3′SL, and polydextrose; GOS, 3′SL, and polydextrose;2′FL, 3′SL, and polydextrose; LNnT, 3′SL, and polydextrose; FOS, GOS,2′FL, LNnT, 6′SL, and polydextrose; FOS, GOS, 2′FL, 6′SL, andpolydextrose; FOS, GOS, LNnT, 6′SL, and polydextrose; FOS, 2′FL, LNnT,6′SL, and polydextrose; GOS, 2′FL, LNnT, 6′SL, and polydextrose; FOS,GOS, 6′SL, and polydextrose; FOS, 2′FL, 6′SL, and polydextrose; FOS,LNnT, 6′SL, and polydextrose; GOS, 2′FL, 6′SL, and polydextrose; GOS,LNnT, 6′SL, and polydextrose; 2′FL, LNnT, 6′SL, and polydextrose; FOS,6′SL, and polydextrose; GOS, 6′SL, and polydextrose; 2′FL, 6′SL, andpolydextrose; LNnT, 6′SL, and polydextrose; FOS, GOS, 2′FL, LNnT, 3′SL,6′SL, and a gum; FOS, GOS, 2′FL, 3′SL, 6′SL, and a gum; FOS, GOS, LNnT,3′SL, 6′SL, and a gum; FOS, 2′FL, LNnT, 3′SL, 6′SL, and a gum; GOS,2′FL, LNnT, 3′SL, 6′SL, and a gum; FOS, GOS, 3′SL, 6′SL, and a gum; FOS,2′FL, 3′SL, 6′SL, and a gum; FOS, LNnT, 3′SL, 6′SL, and a gum; GOS,2′FL, 3′SL, 6′SL, and a gum; GOS, LNnT, 3′SL 6′SL, and a gum; 2′FL,LNnT, 3′SL, 6′SL, and a gum; FOS, 3′SL, 6′SL, and a gum; GOS, 3′SL,6′SL, and a gum; 2′FL, 3′SL, 6′SL, and a gum; LNnT, 3′SL, 6′SL, and agum; FOS, GOS, 2′FL, LNnT, 3′SL, and a gum; FOS, GOS, 2′FL, 3′SL, and agum; FOS, GOS, LNnT, 3′SL, and a gum; FOS, 2′FL, LNnT, 3′SL, and a gum;GOS, 2′FL, LNnT, 3′SL, and a gum; FOS, GOS, 3′SL, and a gum; FOS, 2′FL,3′SL, and a gum; FOS, LNnT, 3′SL, and a gum; GOS, 2′FL, 3′SL, and a gum;GOS, LNnT, 3′SL, and agum; 2′FL, LNnT, 3′SL, and a gum; FOS, 3′SL, and agum; GOS, 3′SL, and a gum; 2′FL, 3′SL, and a gum; LNnT, 3′SL, and a gum;FOS, GOS, 2′FL, LNnT, 6′SL, and a gum; FOS, GOS, 2′FL, 6′SL, and a gum;FOS, GOS, LNnT, 6′SL, and a gum; FOS, 2′FL, LNnT, 6′SL, and a gum; GOS,2′FL, LNnT, 6′SL, and a gum; FOS, GOS, 6′SL, and a gum; FOS, 2′FL, 6′SL,and a gum; FOS, LNnT, 6′SL, and a gum; GOS, 2′FL, 6′SL, and a gum; GOS,LNnT, 6′SL, and a gum; 2′FL, LNnT, 6′SL, and a gum; FOS, 6′SL, and agum; GOS, 6′SL, and a gum; 2′FL, 6′SL, and a gum; and LNnT, 6′SL, and agum.

Probiotics

The nutritional compositions of the present disclosure may, in additionto HMOs (and, optionally, other prebiotic oligosaccharides as describedabove), comprise one or more probiotics. In some embodiments, thenutritional composition includes a combination of HMOs and probioticssuch that the composition provides a synergistic benefit to the end userin promoting the growth of microbiota in the gastrointestinal tract ofinfants.

Probiotics are live microorganisms thought to be healthy for the hostorganism. Lactic acid bacteria (LAB) and bifidobacteria are the mostcommon types of microbes used as probiotics. Probiotics maintain themicrobial ecology of the gut and show physiological, immuno-modulatoryand antimicrobial effects, such that the use of probiotics has beenfound to prevent and treat gastrointestinal diseases and/or disorders,pathogen-induced diarrhea and toxin-producing bacteria, urogenitalinfections, and atopic diseases.

In order for microbes to exhibit beneficial probiotic effects in vivo,the organisms should survive for extended time periods in thegastrointestinal tract. Therefore, it is important that probioticstrains be selected that possess qualities that prevent their rapidremoval by gut contraction. Effective probiotic strains are able tosurvive gastric conditions and colonize the intestine, at leasttemporarily, by adhering to the intestinal epithelium.

Non-limiting examples of probiotic strains for use in the nutritionalcompositions herein include the genus Lactobacillus including L.acidophilus, L. amylovorus, L. brevis, L. bulgaricus, L. casei spp.casei, L. casei spp. rhamnosus, L. crispatus, L. delbrueckii ssp.lactis, L. fermentum, L. helveticus, L. johnsonii, L. paracasei, L.pentosus, L. plantarum, L. reuteri, and L. sake; the genusBifidobacterium including: B. animalis, B. bifidum, B. breve, B.infantis, and B. longum; the genus Pediococcus including: P.acidilactici; the genus Propionibacterium including: P. acidipropionici,P. freudenreichii, P. jensenii, and P. theonii; and the genusStreptococcus including: S. cremoris, S. lactis, and S. thermophilus.Particularly preferred probiotics include probiotics of human infantorigin such as B. infantis M-63, B. infantis ATCC 15697, B. infantis35624, B. infantis CHCC2228, B. infantis BB-02, B. infantis DSM20088,and B. infantis R0033.

The probiotic is present in the nutritional compositions in a totalamount of at least about 10³ CFU/g, including from about 10³ CFU/g toabout 10¹² CFU/g, and including from about 10⁶ CFU/g to about 10⁷ CFU/g.

In some embodiments, the nutritional composition includes a probiotic incombination with a first oligosaccharide including fructooligosaccharideand/or a galactooligosaccharide further in combination with a secondoligosaccharide including at least one HMO such as 2′FL, 3′FL, 3′SL,6′SL, and/or LNnT. In these embodiments, the first oligosaccharide andthe second oligosaccharide are present in the compositions in a weightratio of first oligosaccharide:second oligosaccharide of about 10:1, oreven from about 11:1 to about 8:1.

Macronutrients

The nutritional compositions including the HMO or HMOs may be formulatedto include at least one of protein, fat, and carbohydrate. In manyembodiments, the nutritional compositions will include the HMO or HMOswith protein, carbohydrate and fat.

Although total concentrations or amounts of the fat, protein, andcarbohydrates may vary depending upon the product type (i.e., human milkfortifier, preterm infant formula, infant formula, toddler formula,pediatric formula, follow-on formula, adult nutritional, etc.), productform (i.e., nutritional solid, powder, ready-to-feed liquid, orconcentrated liquid), and targeted dietary needs of the intended user,such concentrations or amounts most typically fall within one of thefollowing embodied ranges, inclusive of any other essential fat,protein, and/or carbohydrate ingredients as described herein.

For the liquid preterm and term infant formulas, carbohydrateconcentrations (including both HMOs and any othercarbohydrate/oligosaccharide sources) most typically range from about 5%to about 40%, including from about 7% to about 30%, including from about10% to about 25%, by weight of the preterm or term infant formula; fatconcentrations most typically range from about 1% to about 30%,including from about 2% to about 15%, and also including from about 3%to about 10%, by weight of the preterm or term infant formula; andprotein concentrations most typically range from about 0.5% to about30%, including from about 1% to about 15%, and also including from about2% to about 10%, by weight of the preterm or term infant formula.

For the liquid human milk fortifiers, carbohydrate concentrations(including both HMOs and any other carbohydrate/oligosaccharide sources)most typically range from about 10% to about 75%, including from about10% to about 50%, including from about 20% to about 40%, by weight ofthe human milk fortifier; fat concentrations most typically range fromabout 10% to about 40%, including from about 15% to about 37%, and alsoincluding from about 18% to about 30%, by weight of the human milkfortifier; and protein concentrations most typically range from about 5%to about 40%, including from about 10% to about 30%, and also includingfrom about 15% to about 25%, by weight of the human milk fortifier.

For the adult nutritional liquids, carbohydrate concentrations(including both HMOs and any other carbohydrate/oligosaccharide sources)most typically range from about 5% to about 40%, including from about 7%to about 30%, including from about 10% to about 25%, by weight of theadult nutritional; fat concentrations most typically range from about 2%to about 30%, including from about 3% to about 15%, and also includingfrom about 5% to about 10%, by weight of the adult nutritional; andprotein concentrations most typically range from about 0.5% to about30%, including from about 1% to about 15%, and also including from about2% to about 10%, by weight of the adult nutritional.

The amount of carbohydrates, fats, and/or proteins in any of the liquidnutritional compositions described herein may also be characterized inaddition to, or in the alternative, as a percentage of total calories inthe liquid nutritional composition as set forth in the following table.These macronutrients for liquid nutritional compositions of the presentdisclosure are most typically formulated within any of the caloricranges (embodiments A-F) described in the following table (eachnumerical value is preceded by the term “about”).

Nutrient % Total Embodiment A Embodiment B Embodiment C Carbohydrate 0-98  2-96 10-75 Protein  0-98  2-96  5-70 Fat  0-98  2-96 20-85Embodiment D Embodiment E Embodiment F Carbohydrate 30-50 25-50 25-50Protein 15-35 10-30  5-30 Fat 35-55  1-20  2-20

In one specific example, liquid infant formulas (both ready-to-feed andconcentrated liquids) include those embodiments in which the proteincomponent may comprise from about 7.5% to about 25% of the caloriccontent of the formula; the carbohydrate component (including both HMOsand any other carbohydrate/oligosaccharide sources) may comprise fromabout 35% to about 50% of the total caloric content of the infantformula; and the fat component may comprise from about 30% to about 60%of the total caloric content of the infant formula. These ranges areprovided as examples only, and are not intended to be limiting.Additional suitable ranges are noted in the following table (eachnumerical value is preceded by the term “about”).

Nutrient % Total Embodiment G Embodiment H Embodiment I Carbohydrates:20-85 30-60 35-55 Fat:  5-70 20-60 25-50 Protein:  2-75  5-50  7-40

When the nutritional composition is a powdered preterm or term infantformula, the protein component is present in an amount of from about 5%to about 35%, including from about 8% to about 12%, and including fromabout 10% to about 12% by weight of the preterm or term infant formula;the fat component is present in an amount of from about 10% to about35%, including from about 25% to about 30%, and including from about 26%to about 28% by weight of the preterm or term infant formula; and thecarbohydrate component (including both HMOs and any othercarbohydrate/oligosaccharide sources) is present in an amount of fromabout 30% to about 85%, including from about 45% to about 60%, includingfrom about 50% to about 55% by weight of the preterm or term infantformula.

For powdered human milk fortifiers, the protein component is present inan amount of from about 1% to about 55%, including from about 10% toabout 50%, and including from about 10% to about 30% by weight of thehuman milk fortifier; the fat component is present in an amount of fromabout 1% to about 30%, including from about 1% to about 25%, andincluding from about 1% to about 20% by weight of the human milkfortifier; and the carbohydrate component (including both HMOs and anyother carbohydrate/oligosaccharide sources) is present in an amount offrom about 15% to about 75%, including from about 15% to about 60%,including from about 20% to about 50% by weight of the human milkfortifier.

For powdered adult nutritionals, the protein component is present in anamount of from about 10% to about 90%, including from about 30% to about80%, and including from about 40% to about 75% by weight of the adultnutritional; the fat component is present in an amount of from about0.5% to about 20%, including from about 1% to about 10%, and includingfrom about 2% to about 5% by weight of the adult nutritional; and thecarbohydrate component (including both HMOs and any othercarbohydrate/oligosaccharide sources) is present in an amount of fromabout 5% to about 40%, including from about 7% to about 30%, includingfrom about 10% to about 25% by weight of the adult nutritional.

The total amount or concentration of fat, carbohydrate, and protein, inthe powdered nutritional compositions of the present disclosure can varyconsiderably depending upon the selected composition and dietary ormedical needs of the intended user. Additional suitable examples ofmacronutrient concentrations are set forth below. In this context, thetotal amount or concentration refers to all fat, carbohydrate, andprotein sources in the powdered composition. For powdered nutritionalcompositions, such total amounts or concentrations are most typicallyand preferably formulated within any of the embodied ranges described inthe following table (each numerical value is preceded by the term“about”).

Nutrient % Total Embodiment J Embodiment K Embodiment L Carbohydrate1-85 30-60 35-55 Fat 5-70 20-60 25-50 Protein 2-75  5-50  7-40

The nutritional compositions of the present disclosure may optionallycomprise any source or sources of fat. Suitable sources of fat for useherein include any fat or fat source that is suitable for use in an oralnutritional composition and is compatible with the essential elementsand features of such composition. For example, in one specificembodiment, the fat is derived from long chain polyunsaturated fattyacids (LCPUFAs).

Exemplary LCPUFAs for use in the nutritional compositions include, forexample, w-3 LCPUFAs and w-6 LCPUFAs. Specific LCPUFAs includedocosahexaenoic acid (DHA), eicosapentaenoic acid (EPA),docosapentaenoic acid (DPA), arachidonic acid (ARA), linoleic acid,linolenic acid (alpha linolenic acid) and gamma-linolenic acid derivedfrom oil sources such as plant oils, marine plankton, fungal oils, andfish oils. In one particular embodiment, the LCPUFAs are derived fromfish oils such as menhaden, salmon, anchovy, cod, halibut, tuna, orherring oil. Particularly preferred LCPUFAs for use in the nutritionalcompositions with the HMOs include DHA, ARA, EPA, DPA, and combinationsthereof

In order to reduce potential side effects of high dosages of LCPUFAs inthe nutritional compositions, the content of LCPUFAs preferably does notexceed 3% by weight of the total fat content, including below 2% byweight of the total fat content, and including below 1% by weight of thetotal fat content in the nutritional composition.

The LCPUFA may be provided as free fatty acids, in triglyceride form, indiglyceride form, in monoglyceride form, in phospholipid form, inesterfied form or as a mixture of one or more of the above, preferablyin triglyceride form. In another specific embodiment, the fat is derivedfrom short chain fatty acids.

Additional non-limiting examples of suitable fats or sources thereof foruse in the nutritional compositions described herein include coconutoil, fractionated coconut oil, soybean oil, corn oil, olive oil,safflower oil, high oleic safflower oil, oleic acids (EMERSOL 6313 OLEICACID, Cognis Oleochemicals, Malaysia), MCT oil (medium chaintriglycerides), sunflower oil, high oleic sunflower oil, palm and palmkernel oils, palm olein, canola oil, marine oils, fish oils, fungaloils, algae oils, cottonseed oils, and combinations thereof.

Protein

The nutritional compositions of the present disclosure may optionallyfurther comprise protein. Any protein source that is suitable for use inoral nutritional compositions and is compatible with the essentialelements and features of such compositions is suitable for use in thenutritional compositions.

Non-limiting examples of suitable proteins or sources thereof for use inthe nutritional compositions include hydrolyzed, partially hydrolyzed ornon-hydrolyzed proteins or protein sources, which may be derived fromany known or otherwise suitable source such as milk (e.g., casein,whey), animal (e.g., meat, fish), cereal (e.g., rice, corn), vegetable(e.g., soy) or combinations thereof. Non-limiting examples of suchproteins include milk protein isolates, milk protein concentratesasdescribed herein, casein protein isolates, extensively hydrolyzedcasein, whey protein, sodium or calcium caseinates, whole cow milk,partially or completely defatted milk, soy protein isolates, soy proteinconcentrates, and so forth. In one specific embodiment, the nutritionalcompositions include a protein source derived from milk proteins ofhuman and/or bovine origin.

In one embodiment, the protein source is a hydrolyzed proteinhydrolysate. In this context, the terms “hydrolyzed protein” or “proteinhydrolysates” are used interchangeably herein and include extensivelyhydrolyzed proteins, wherein the degree of hydrolysis is most often atleast about 20%, including from about 20% to about 80%, and alsoincluding from about 30% to about 80%, even more preferably from about40% to about 60%. The degree of hydrolysis is the extent to whichpeptide bonds are broken by a hydrolysis method. The degree of proteinhydrolysis for purposes of characterizing the extensively hydrolyzedprotein component of these embodiments is easily determined by one ofordinary skill in the formulation arts by quantifying the amino nitrogento total nitrogen ratio (AN/TN) of the protein component of the selectedliquid formulation. The amino nitrogen component is quantified by USPtitration methods for determining amino nitrogen content, while thetotal nitrogen component is determined by the Tecator Kjeldahl method,all of which are well known methods to one of ordinary skill in theanalytical chemistry art.

Suitable hydrolyzed proteins may include soy protein hydrolysate, caseinprotein hydrolysate, whey protein hydrolysate, rice protein hydrolysate,potato protein hydrolysate, fish protein hydrolysate, egg albumenhydrolysate, gelatin protein hydrolysate, combinations of animal andvegetable protein hydrolysates, and combinations thereof Particularlypreferred protein hydrolysates include whey protein hydrolysate andhydrolyzed sodium caseinate.

When used in the nutritional compositions, the protein source mayinclude at least about 20% (by weight total protein) proteinhydrolysate, including from about 30% to 100% (by weight total protein)protein hydrolysate, and including from about 40% to about 80% (byweight total protein) protein hydrolysate, and including about 50% (byweight total protein) protein hydrolysate. In one particularembodiment,the nutritional composition includes 100% (by weight total protein)protein hydrolysate.

Carbohydrate

The nutritional compositions of the present disclosure may furtheroptionally comprise any carbohydrates that are suitable for use in anoral nutritional composition and are compatible with the essentialelements and features of such compositions.

Non-limiting examples of suitable carbohydrates or sources thereof foruse in the nutritional compositions described herein may includemaltodextrin, hydrolyzed or modified starch or cornstarch, glucosepolymers, corn syrup, corn syrup solids, rice-derived carbohydrates,pea-derived carbohydrates, potato-derived carbohydrates, tapioca,sucrose, glucose, fructose, lactose, high fructose corn syrup, honey,sugar alcohols (e.g., maltitol, erythritol, sorbitol), artificialsweeteners (e.g., sucralose, acesulfame potassium, stevia) andcombinations thereof A particularly desirable carbohydrate is a lowdextrose equivalent (DE) maltodextrin.

Other Optional Ingredients

The nutritional compositions of the present disclosure may furthercomprise other optional components that may modify the physical,chemical, aesthetic or processing characteristics of the compositions orserve as pharmaceutical or additional nutritional components when usedin the targeted population. Many such optional ingredients are known orotherwise suitable for use in medical food or other nutritional productsor pharmaceutical dosage forms and may also be used in the compositionsherein, provided that such optional ingredients are safe for oraladministration and are compatible with the essential and otheringredients in the selected product form.

Non-limiting examples of such optional ingredients includepreservatives, emulsifying agents, buffers, pharmaceutical actives,anti-inflammatory agents, additional nutrients as described herein,colorants, flavors, thickening agents and stabilizers, emulsifyingagents, lubricants, and so forth.

The nutritional compositions may further comprise a sweetening agent,preferably including at least one sugar alcohol such as maltitol,erythritol, sorbitol, xylitol, mannitol, isolmalt, and lactitol, andalso preferably including at least one artificial or high potencysweetener such as acesulfame K, aspartame, sucralose, saccharin, stevia,and tagatose. These sweetening agents, especially as a combination of asugar alcohol and an artificial sweetener, are especially useful informulating liquid beverage embodiments of the present disclosure havinga desirable favor profile. These sweetener combinations are especiallyeffective in masking undesirable flavors sometimes associated with theaddition of vegetable proteins to a liquid beverage. Optional sugaralcohol concentrations in the nutritional composition may range from atleast 0.01%, including from 0.1% to about 10%, and also including fromabout 1% to about 6%, by weight of the nutritional composition. Optionalartificial sweetener concentrations may range from about 0.01%,including from about 0.05% to about 5%, also including from about 0.1%to about 1.0%, by weight of the nutritional composition.

A flowing agent or anti-caking agent may be included in the nutritionalcompositions as described herein to retard clumping or caking of thepowder over time and to make a powder embodiment flow easily from itscontainer. Any known flowing or anti-caking agents that are known orotherwise suitable for use in a nutritional powder or product form aresuitable for use herein, non-limiting examples of which includetricalcium phosphate, silicates, and combinations thereof. Theconcentration of the flowing agent or anti-caking agent in thenutritional composition varies depending upon the product form, theother selected ingredients, the desired flow properties, and so forth,but most typically range from about 0.1% to about 4%, including fromabout 0.5% to about 2%, by weight of the nutritional composition.

A stabilizer may also be included in the nutritional compositions. Anystabilizer that is known or otherwise suitable for use in a nutritionalcomposition is also suitable for use herein, some non-limiting examplesof which include gums such as xanthan gum. The stabilizer may representfrom about 0.1% to about 5.0%, including from about 0.5% to about 3%,including from about 0.7% to about 1.5%, by weight of the nutritionalcomposition.

Additionally, the nutritional compositions may comprise one or moreantioxidants to provide nutritional support, as well as to reduceoxidative stress. Any antioxidants suitable for oral administration maybe included for use in the nutritional compositions of the presentdisclosure, including, for example, vitamin A, vitamin E, vitamin C,retinol, tocopherol, and carotenoids.

In one specific embodiment, the antioxidants for use in the nutritionalcompositions include carotenoids such as lutein, zeaxanthin, lycopene,beta-carotene, and combinations thereof, and particularly, combinationsof the carotenoids lutein, lycopene, and beta-carotene. Nutritionalcompositions containing these combinations, as selected and definedherein, can be used to modulate inflammation and/or levels of C-reactiveprotein in preterm and term infants.

The nutritional compositions may further comprise any of a variety ofother vitamins or related nutrients, non-limiting examples of whichinclude vitamin D, vitamin K, thiamine, riboflavin, pyridoxine, vitaminB12, niacin, folic acid, pantothenic acid, biotin, choline, inositol,salts and derivatives thereof, and combinations thereof

The nutritional compositions may further comprise any of a variety ofother additional minerals, non-limiting examples of which includecalcium, phosphorus, magnesium, iron, zinc, manganese, copper, sodium,potassium, molybdenum, chromium, chloride, and combinations thereof

The nutritional compositions of the present disclosure may additionallycomprise nucleotides and/or nucleotide precursors selected from thegroup consisting of nucleoside, purine base, pyrimidine base, ribose anddeoxyribose to further improve intestinal barrier integrity and/ormaturation. The nucleotide may be in monophosphate, diphosphate, ortriphosphate form. The nucleotide may be a ribonucleotide or adeoxyribonucleotide. The nucleotides may be monomeric, dimeric, orpolymeric (including RNA and DNA). The nucleotide may be present in thenutritional composition as a free acid or in the form of a salt,preferably a monosodium salt.

Suitable nucleotides and/or nucleosides for use in the nutritionalcompositions include one or more of cytidine 5′-monophosphate, uridine5′-monophosphate, adenosine 5′-monophosphate, guanosine5′-1-monophosphate, and/or inosine 5′-monophosphate, more preferablycytidine 5′-monophosphate, uridine 5′-monophosphate, adenosine5′-monophosphate, guanosine 5′-monophosphate, and inosine5′-monophosphate.

Methods of Manufacture

The nutritional compositions of the present disclosure may be preparedby any known or otherwise effective manufacturing technique forpreparing the selected product solid or liquid form. Many suchtechniques are known for any given product form such as nutritionalliquids or powders and can easily be applied by one of ordinary skill inthe art to the nutritional compositions described herein.

The nutritional compositions of the present disclosure can therefore beprepared by any of a variety of known or otherwise effective formulationor manufacturing methods. In one suitable manufacturing process, forexample, at least three separate slurries are prepared, including aprotein-in-fat (PIF) slurry, a carbohydrate-mineral (CHO-MN) slurry, anda protein-in-water (PIW) slurry. The PIF slurry is formed by heating andmixing the oil (e.g., canola oil, corn oil, etc.) and then adding anemulsifier (e.g., lecithin), fat soluble vitamins, and a portion of thetotal protein (e.g., milk protein concentrate, etc.) with continued heatand agitation. The CHO-MIN slurry is formed by adding with heatedagitation to water: minerals (e.g., potassium citrate, dipotassiumphosphate, sodium citrate, etc.), trace and ultra trace minerals (TM/UTMpremix), thickening or suspending agents (e.g. avicel, gellan,carrageenan). The resulting CHO-MIN slurry is held for 10 minutes withcontinued heat and agitation before adding additional minerals (e.g.,potassium chloride, magnesium carbonate, potassium iodide, etc.), and/orcarbohydrates (e.g., HMOs, fructooligosaccharide, sucrose, corn syrup,etc.). The PIW slurry is then formed by mixing with heat and agitationthe remaining protein, if any.

The resulting slurries are then blended together with heated agitationand the pH adjusted to 6.6-7.0, after which the composition is subjectedto high-temperature short-time (HTST) processing during which thecomposition is heat treated, emulsified and homogenized, and thenallowed to cool. Water soluble vitamins and ascorbic acid are added, thepH is adjusted to the desired range if necessary, flavors are added, andwater is added to achieve the desired total solid level. The compositionis then aseptically packaged to form an aseptically packaged nutritionalemulsion. This emulsion can then be further diluted, heat-treated, andpackaged to form a ready-to-feed or concentrated liquid, or it can beheat-treated and subsequently processed and packaged as areconstitutable powder, e.g., spray dried, drymixed, agglomerated.

The nutritional solid, such as a spray dried nutritional powder ordrymixed nutritional powder, may be prepared by any collection of knownor otherwise effective techniques, suitable for making and formulating anutritional powder.

For example, when the nutritional powder is a spray dried nutritionalpowder, the spray drying step may likewise include any spray dryingtechnique that is known for or otherwise suitable for use in theproduction of nutritional powders. Many different spray drying methodsand techniques are known for use in the nutrition field, all of whichare suitable for use in the manufacture of the spray dried nutritionalpowders herein.

One method of preparing the spray dried nutritional powder comprisesforming and homogenizing an aqueous slurry or liquid comprisingpredigested fat, and optionally protein, carbohydrate, and other sourcesof fat, and then spray drying the slurry or liquid to produce a spraydried nutritional powder. The method may further comprise the step ofspray drying, drymixing, or otherwise adding additional nutritionalingredients, including any one or more of the ingredients describedherein, to the spray dried nutritional powder.

Other suitable methods for making nutritional compositions aredescribed, for example, in U.S. Pat. No. 6,365,218 (Borschel, et al.),U.S. Pat. No. 6,589,576 (Borschel, et al.), U.S. Pat. No. 6,306,908(Carlson, et al.), U.S. Patent Application No. 20030118703 A1 (Nguyen,et al.), which descriptions are incorporated herein by reference to theextent that they are consistent herewith.

Methods of Use

The nutritional compositions as described herein can be used to addressone or more of the diseases, disorders, or conditions discussed herein,or can be used to provide one or more of the benefits described herein,to preterm infants, infants, toddlers, children, and adults, includingpregnant women. The preterm infant, infant, toddler, child, adult andpregnant women utilizing the nutritional compositions described hereinmay actually have or be afflicted with the disease or conditiondescribed, or may be susceptible to, or at risk of, getting the diseaseor condition (that is, may not actually yet have the disease orcondition, but is at elevated risk as compared to the general populationfor getting it due to certain conditions, family history, etc.) Whetherthe preterm infant, infant, toddler, child, adult, and pregnant womenactually have the disease or condition, or is at risk or susceptible tothe disease or condition, the preterm infant, infant, toddler, child,adult, and pregnant women are classified herein as “in need ofassistance in dealing with and combating the disease or condition. Forexample, the preterm infant, infant, toddler, child, adult and pregnantwomen may actually have respiratory inflammation or may be at risk ofgetting respiratory inflammation (susceptible to getting respiratoryinflammation) due to family history or other medical conditions, forexample. Whether the preterm infant, infant, toddler, child, adult, andpregnant women actually has the disease or condition, or is only at riskor susceptible to getting the disease or condition, it is within thescope of the present disclosure to assist the preterm infant, infant,toddler, child, adult and pregnant women with the nutritionalcompositions described herein.

Based on the foregoing, because some of the method embodiments of thepresent disclosure are directed to specific subsets or subclasses ofidentified individuals (that is, the subset or subclass of individuals“in need” of assistance in addressing one or more specific diseases orspecific conditions noted herein), not all preterm infants, infants,toddlers, children, adults and pregnant women will fall within thesubset or subclass of preterm infants, infants, toddlers, children,adults, and pregnant women as described herein for certain diseases orconditions.

The nutritional compositions as described herein comprise HMOs, alone orin combination with one or more additional components, to provide anutritional source for improving at least the intestinal/gut function.Specifically, the nutritional compositions can stimulate enteric nervecells in the gastrointestinal tract of an individual to improveintestinal/gut barrier integrity; improve feeding tolerance (e.g.,reduced diarrhea, loose stools, gas, and bloating); reduce colic ininfants; protect against necrotizing enterocolitis and other disordersof prematurity; address gastrointestinal diseases and disordersassociated with the enteric nervous system; address gastrointestinaldiseases and disorders of gut contractility and inflammation; correcteffects of gut dysbiosis; and affect long-term modulation of allergictolerance.

More particularly, in some embodiments, the nutritional compositions maybe administered to an individual having, susceptible to, or at risk of,gastrointestinal diseases and disorders associated with the entericnervous system and/or associated with gut contractility andinflammation, which may include, for example, irritable bowel syndrome,colitis (e.g., necrotizing enterocolitis, Crohn's disease, ischemiccolitis, cryptosporidium enterocolitis, pseudomembranous colitis,cytomegalovirus, ulcerative colitis), food intolerance, and foodallergies.

Along with improved growth and maturation of an individual's immunesystem as described above, the use of the nutritional compositions ofthe present disclosure may also function to enhance the individual'sability to resist microbial infection and to promote the growth ofbeneficial microbiota in the gastrointestinal tract of an infant,toddler, child, or adult.

Further, when used in combination with LCPUFAs and/or antioxidants, andparticularly, with carotenoids, the HMOs can reduce oxidative stress,which is a metabolic condition in which there is an increased productionand accumulation of oxidized biomolecules such as lipid peroxides andtheir catabolites, protein carbonyls, and oxidatively damaged DNA. Theoutcomes of oxidative stress range from unwanted changes in metabolismto inflammation and cell and tissue death. Accordingly, by reducing theincidence of unregulated inflammation and oxidation in the infant,damage to the tissue lining and cell death is reduced, further reducingthe incidence of inflammatory diseases, such as necrotizingenterocolitis (NEC).

Additionally, the nutritional compositions of the present disclosure mayalso be used to improve cognition in individuals, particularly inindividuals susceptible to, or at risk of, neurodegenerative diseases,which may include, for example, Alzheimer's disease, Huntington'sdisease, Parkinson's disease, and schizophrenia, or in individualssuffering from conditions caused by impaired cognitive development orneurodevelopmental conditions, such as attention deficit hyperactivitydisorder and autism.

EXAMPLES

The following examples illustrate specific embodiments and/or featuresof the nutritional compositions and methods of the present disclosure.The examples are given solely for the purpose of illustration and arenot to be construed as limitations of the present disclosure, as manyvariations thereof are possible without departing from the spirit andscope of the disclosure. All exemplified amounts are weight percentagesbased upon the total weight of the composition, unless otherwisespecified.

The exemplified compositions are shelf stable nutritional compositionsprepared in accordance with the manufacturing methods described herein,such that each exemplified composition, unless otherwise specified,includes an aseptically processed embodiment and a retort packagedembodiment.

The nutritional liquid embodiments are aqueous oil-in-water emulsionsthat are packaged in 240 mL plastic containers and remain physicallystable for 12-18 months after composition/packaging at storagetemperatures ranging from 1-25° C.

Examples 1-5

Examples 1-5 illustrate ready-to-feed nutritional emulsions of thepresent disclosure, the ingredients of which are listed in the tablebelow. All ingredient amounts are listed as kilogram per 1000 kilogrambatch of product, unless otherwise specified.

Ingredient Ex. 1 Ex. 2 Ex. 3 Ex. 4 Ex. 5 Water Q.S. Q.S. Q.S. Q.S. Q.S.Condensed Skim Milk 86.64 86.64 86.64 86.64 86.64 Lactose 54.80 54.8054.80 54.80 54.80 High oleic safflower oil 14.10 14.10 14.10 14.10 14.10Soybean oil 10.6 10.6 10.6 10.6 10.6 Coconut oil 10.1 10.1 10.1 10.110.1 2′ fucosyllactose (2′FL) 0.1896 0.1801 0.1706 0.1991 0.2086Galactooligosaccharides (GOS) 8.630 8.630 8.630 8.630 8.630 Whey proteinconcentrate 6.40 6.40 6.40 6.40 6.40 Potassium citrate  478.9 g  478.9 g 478.9 g  478.9 g  478.9 g Calcium carbonate 448.28 g 445.28 g 445.28 g448.28 g 448.28 g Soy lecithin 355.74 g 355.74 g 355.74 g 355.74 g355.74 g Stabilizer 355.74 g 355.74 g 355.74 g 355.74 g 355.74 g ARA oil368.01 g 368.01 g 368.01 g 368.01 g 368.01 g Nucleotide/chloride premix293.26 g 293.26 g 293.26 g 293.26 g 293.26 g Potassium chloride 226.45 g226.45 g 226.45 g 226.45 g 226.45 g Ascorbic acid 445.94 g 445.94 g445.94 g 445.94 g 445.94 g Vitamin mineral premix 142.88 g 142.88 g142.88 g 142.88 g 142.88 g DHA oil  137.8 g  137.8 g  137.8 g  137.8 g 137.8 g Carrageenan  180.0 g  180.0 g  180.0 g  180.0 g  180.0 gMagnesium chloride  55.0 g  55.0 g  55.0 g  55.0 g  55.0 g Ferroussulfate  58.0 g  58.0 g  58.0 g  58.0 g  58.0 g Choline chloride  53.9 g 53.9 g  53.9 g  53.9 g  53.9 g Vitamin A, D₃, E, K₁ premix  47.40 g 47.40 g  47.40 g  47.40 g  47.40 g Citric acid  29.77 g  29.77 g  29.77g  29.77 g  29.77 g Probiotic 1.0 1.0 1.0 1.0 1.0 Mixed carotenoidpremix  26.40 g  26.40 g  26.40 g  26.40 g  26.40 g Sodium chloride ANAN AN AN AN L-camitine  3.31 g  3.31 g  3.31 g  3.31 g  3.31 gTricalcium phosphate  15.65 g  15.65 g  15.65 g  15.65 g  15.65 gPotassium phosphate monobasic  13.67 g  13.67 g  13.67 g  13.67 g  13.67g Riboflavin  2.42 g  2.42 g  2.42 g  2.42 g  2.42 g Potassium hydroxideAN AN AN AN AN AN = as needed

Examples 6-10

Examples 6-10 illustrate ready-to-feed nutritional emulsions of thepresent disclosure, the ingredients of which are listed in the tablebelow. All ingredient amounts are listed as kilogram per 1000 kilogrambatch of product, unless otherwise specified.

Ingredient Ex. 6 Ex. 7 Ex. 8 Ex. 9 Ex. 10 Water Q.S. Q.S. Q.S. Q.S. Q.S.Condensed Skim Milk 86.64 86.64 86.64 86.64 86.64 Lactose 54.80 54.8054.80 54.80 54.80 High oleic safflower oil 14.10 14.10 14.10 14.10 14.10Soybean oil 10.6 10.6 10.6 10.6 10.6 Coconut oil 10.1 10.1 10.1 10.110.1 2′ fucosyllactose (2′FL) 0.0948 0.09005 0.0853 0.0995 0.1043Lacto-N-neotetraose (LNnT) 0.0948 0.09005 0.0853 0.0995 0.1043Galactooligosaccharides (GOS) 8.630 8.630 8.630 8.630 8.630 Whey proteinconcentrate 6.40 6.40 6.40 6.40 6.40 Potassium citrate  478.9 g  478.9 g 478.9 g  478.9 g  478.9 g Calcium carbonate 448.28 g 448.28 g 448.28 g448.28 g 448.28 g Soy lecithin 355.74 g 355.74 g 355.74 g 355.74 g355.74 g Stabilizer 355.74 g 355.74 g 355.74 g 355.74 g 355.74 g ARA oil368.01 g 368.01 g 368.01 g 368.01 g 368.01 g Nucleotide/chloride premix293.26 g 293.26 g 293.26 g 293.26 g 293.26 g Potassium chloride 226.45 g226.45 g 226.45 g 226.45 g 226.45 g Ascorbic acid 445.94 g 445.94 g445.94 g 445.94 g 445.94 g Vitamin mineral premix 142.88 g 142.88 g142.88 g 142.88 g 142.88 g DHA oil  137.8 g  137.8 g  137.8 g  137.8 g 137.8 g Carrageenan  180.0 g  180.0 g  180.0 g  180.0 g  180.0 gMagnesium chloride  55.0 g  55.0 g  55.0 g  55.0 g  55.0 g Ferroussulfate  58.0 g  58.0 g  58.0 g  58.0 g  58.0 g Choline chloride  53.9 g 53.9 g  53.9 g  53.9 g  53.9 g Vitamin A, D₃, E, K₁ premix  47.40 g 47.40 g  47.40 g  47.40 g  47.40 g Citric acid  29.77 g  29.77 g  29.77g  29.77 g  29.77 g Probiotic 1.0 0.95 0.90 1.05 1.10 Mixed carotenoidpremix  26.40 g  26.40 g  26.40 g  26.40 g  26.40 g Sodium chloride ANAN AN AN AN L-camitine  3.31 g  3.31 g  3.31 g  3.31 g  3.31 gTricalcium phosphate  15.65 g  15.65 g  15.65 g  15.65 g  15.65 gPotassium phosphate monobasic  13.67 g  13.67 g  13.67 g  13.67 g  13.67g Riboflavin  2.42 g  2.42 g  2.42 g  2.42 g  2.42 g Potassium hydroxideAN AN AN AN AN AN = as needed

Examples 11-15

Examples 11-15 illustrate concentrated liquid emulsions of the presentdisclosure, the ingredients of which are listed in the table below. Allingredient amounts are listed as kilogram per 1000 kilogram batch ofproduct, unless otherwise specified.

Ingredient Ex. 11 Ex. 12 Ex. 13 Ex. 14 Ex. 15 Water Q.S. Q.S. Q.S. Q.S.Q.S. Condensed Skim Milk 166.6 166.6 166.6 166.6 166.6 Lactose 106.1106.1 106.1 106.1 106.1 High oleic safflower oil 27.16 27.16 27.16 27.1627.16 Soybean oil 20.42 20.42 20.42 20.42 20.42 Coconut oil 19.48 19.4819.48 19.48 19.48 2′ fucosyllactose (2′FL) 0.1896 0.1188 0.0853 0.24140.2560 Galactooligosaccharides (GOS) 16.71 16.71 16.71 16.71 16.71 Wheyprotein concentrate 12.20 12.20 12.20 12.20 12.20 Potassium citrate894.5 g 894.5 g 894.5 g 894.5 g 894.5 g Calcium carbonate 1.072 1.0721.072 1.072 1.072 Monoglycerides 690.0 g 690.0 g 690.0 g 690.0 g 690.0 gSoy lecithin 690.0 g 690.0 g 690.0 g 690.0 g 690.0 g ARA oil 684.2 g684.2 g 684.2 g 684.2 g 684.2 g Nucleotide/chloride premix 568.9 g 568.9g 568.9 g 568.9 g 568.9 g Potassium chloride 480.8 g 480.8 g 480.8 g480.8 g 480.8 g Ascorbic acid 958.6 g 958.6 g 958.6 g 958.6 g 958.6 gVitamin mineral premix 276.9 g 276.9 g 276.9 g 276.9 g 276.9 g DHA oil256.1 g 256.1 g 256.1 g 256.1 g 256.1 g Carrageenan 200.0 g 200.0 g200.0 g 200.0 g 200.0 g Magnesium chloride 174.7 g 174.7 g 174.7 g 174.7g 174.7 g Ferrous sulfate 112.7 g 112.7 g 112.7 g 112.7 g 112.7g Cholinechloride 104.8 g 104.8 g 104.8 g 104.8 g 104.8 g Vitamin A, D₃, E, K₁premix 86.90 g 86.90 g 86.90 g 86.90 g 86.90 g Citric acid 64.55 g 64.55g 64.55 g 64.55 g 64.55 g Mixed carotenoid premix 45.63 g 45.63 g 45.63g 45.63 g 45.63 g Sodium chloride AN AN AN AN AN L-camitine 6.371 g6.371 g 6.371 g 6.371 g 6.371 g Riboflavin 2.921 g 2.921 g 2.921 g 2.921g 2.921 g Vitamin A Palmitate 1.504 g 1.504 g 1.504 g 1.504 g 1.504 gPotassium hydroxide 659.8 g 659.8 g 659.8 g 659.8 g 659.8 g Tricalciumphosphate AN AN AN AN AN Potassium phosphate AN AN AN AN AN AN = asneeded

Examples 16-20

Examples 16-20 illustrate spray dried nutritional powders of the presentdisclosure, the ingredients of which are listed in the table below. Allingredient amounts are listed as kilogram per 1000 kilogram batch ofproduct, unless otherwise specified.

Ingredient Ex. 16 Ex. 17 Ex. 18 Ex. 19 Ex. 20 Nonfat dry milk 456.9456.9 456.9 456.9 456.9 Lactose 259.0 259.0 259.0 259.0 259.0 High oleicsunflower oil 93.9 93.9 93.9 93.9 93.9 Soy oil 70.4 70.4 70.4 70.4 70.4Coconut oil 67.1 67.1 67.1 67.1 67.1 2′ fucosyllactose (2′FL) 0.75840.7204 0.6824 0.7964 0.8344 Galactooligosaccharide (GOS) 53.5 53.5 53.553.5 53.5 Probiotic 1.0 0.95 0.90 1.05 1.10 Flavoring agent 6.2 6.2 6.26.2 6.2 Calcium carbonate 4.8 4.8 4.8 4.8 4.8 Potassium citrate 4.7 4.74.7 4.7 4.7 Oligofructose (FOS) 2.9 2.9 2.9 2.9 2.9 Ascorbic acid 2.02.0 2.0 2.0 2.0 Nucleotide/Choline Premix 1.8 1.8 1.8 1.8 1.8 ARA oil1.8 1.8 1.8 1.8 1.8 Vitamin/Trace Mineral Premix 1.5 1.5 1.5 1.5 1.5Sodium chloride 1.3 1.3 1.3 1.3 1.3 Lecithin 1.2 1.2 1.2 1.2 1.2 Sodiumcitrate 982.2 g 982.2 g 982.2 g 982.2 g 982.2 g DHA oil 882.1 g 882.1 g882.1 g 882.1 g 882.1 g Magnesium chloride 477.4 g 477.4 g 477.4 g 477.4g 477.4 g Vitamin A, D3, E, K1 Premix 314.7 g 314.7 g 314.7 g 314.7 g314.7 g Ascorbyl Palmitate 278.8 g 278.8 g 278.8 g 278.8 g 278.8 gAntioxidant 137.3 g 137.3 g 137.3 g 137.3 g 137.3 g Tocopheryl acetate 32.0 g  32.0 g  32.0 g  32.0 g  32.0 g Beta-carotene 30%  11.0 g  11.0g  11.0 g  11.0 g  11.0 g Potassium iodide  2.5 g  2.5 g  2.5 g  2.5 g 2.5 g Riboflavin  2.0 g  2.0 g  2.0 g  2.0 g  2.0 g Magnesium sulfate499.5 mg 499.5 mg 499.5 mg 499.5 mg 499.5 mg Potassium phosphate dibasicAN AN AN AN AN Potassium chloride AN AN AN AN AN Tricalcium phosphate ANAN AN AN AN Potassium hydroxide AN AN AN AN AN Calcium hydroxide AN ANAN AN AN Sodium hydroxide AN AN AN AN AN Water Q.S. Q.S. Q.S. Q.S. Q.S.AN = as needed

Examples 21-25

Examples 21-25 illustrate spray dried nutritional powders of the presentdisclosure, the ingredients of which are listed in the table below. Allingredient amounts are listed as kilogram per 1000 kilogram batch ofproduct, unless otherwise specified.

Ingredient Ex. 21 Ex. 22 Ex. 23 Ex. 24 Ex. 25 Water Q.S. Q.S. Q.S. Q.S.Q.S. Corn syrup 308.9 308.9 308.9 308.9 308.9 Maltodextrin 297.1 297.1297.1 297.1 297.1 Sucrose 112.4 112.4 112.4 112.4 112.4 High Oleicsunflower oil 84.9 84.9 84.9 84.9 84.9 Sodium caseinate 73.0 73.0 73.073.0 73.0 Calcium caseinate 50.2 50.2 50.2 50.2 50.2 2′ fucosyllactose(2′FL) 0.7584 0.7204 0.6824 0.7964 0.8344 Inulin oligofructose 47.0 47.047.0 47.0 47.0 Soy oil 38.3 38.3 38.3 38.3 38.3 Isolated soy protein35.9 35.9 35.9 35.9 35.9 Milk protein isolate 16.3 16.3 16.3 16.3 16.3Canola oil 13.7 13.7 13.7 13.7 13.7 Sodium citrate 9.8 9.8 9.8 9.8 9.8Potassium citrate 9.7 9.7 9.7 9.7 9.7 Tricalcium phosphate 9.0 9.0 9.09.0 9.0 Flavoring agent 7.3 7.3 7.3 7.3 7.3 Magnesium chloride 6.2 6.26.2 6.2 6.2 Potassium chloride 5.5 5.5 5.5 5.5 5.5 Choline chloride 1.71.7 1.7 1.7 1.7 Vitamin premix 950.0 g 950.0 g 950.0 g 950.0 g 950.0 gAscorbic acid 755.0 g 755.0 g 755.0 g 755.0 g 755.0 g Vitamin/tracemineral premix 465.0 g 465.0 g 465.0 g 465.0 g 465.0 g Potassiumhydroxide 215.9 g 215.9 g 215.9 g 215.9 g 215.9 g Potassium phosphatedibasic 185.8 g 185.8 g 185.8 g 185.8 g 185.8 g Ascorbyl palmitate 164.7g 164.7 g 164.7 g 164.7 g 164.7 g Antioxidant  82.3 g  82.3 g  82.3 g 82.3 g  82.3 g Vitamin A, D3, E, K1 premix  82.3 g  82.3 g  82.3 g 82.3 g  82.3 g Vitamin A palmitate  16.5 g  16.5 g  16.5 g  16.5 g 16.5 g Ferrous sulfate  12.0 g  12.0 g  12.0 g  12.0 g  12.0 g Betacarotene 30%  5.5 g  5.5 g  5.5 g  5.5 g  5.5 g Vitamin D3 oil  1.0 g 1.0 g  1.0 g  1.0 g  1.0 g Potassium iodide 800.0 mg 800.0 mg 800.0 mg800.0 mg 800.0 mg Citric acid AN AN AN AN AN Potassium hydroxide 40% ANAN AN AN AN Maltodextrin AN AN AN AN AN Magnesium sulfate AN AN AN AN ANSodium chloride AN AN AN AN AN Calcium carbonate AN AN AN AN AN AN = asneeded

Examples 26-30

Examples 26-30 illustrate ready-to-feed nutritional emulsions of thepresent disclosure, the ingredients of which are listed in the tablebelow. All ingredient amounts are listed as kilogram per 1000 kilogrambatch of product, unless otherwise specified.

Ingredient Ex. 26 Ex. 27 Ex. 28 Ex. 29 Ex. 30 Water Q.S. Q.S. Q.S. Q.S.Q.S. Condensed Skim Milk 86.64 86.64 86.64 86.64 86.64 Lactose 54.8054.80 54.80 54.80 54.80 High oleic safflower oil 14.10 14.10 14.10 14.1014.10 Soybean oil 10.6 10.6 10.6 10.6 10.6 Coconut oil 10.1 10.1 10.110.1 10.1 2′ fucosyllactose (2′FL) 0.0948 0.09005 0.0853 0.0995 0.10436′-sialyllactose (6′SL) 0.0948 0.09005 0.0853 0.0995 0.1043Galactooligosaccharides (GOS) 8.630 8.630 8.630 8.630 8.630 Whey proteinconcentrate 6.40 6.40 6.40 6.40 6.40 Potassium citrate  478.9 g  478.9 g 478.9 g  478.9 g  478.9 g Calcium carbonate 448.28 g 448.28 g 448.28 g448.28 g 448.28 g Soy lecithin 355.74 g 355.74 g 355.74 g 355.74 g355.74 g Stabilizer 355.74 g 355.74 g 355.74 g 355.74 g 355.74 g ARA oil368.01 g 368.01 g 368.01 g 368.01 g 368.01 g Nucleotide/chloride premix293.26 g 293.26 g 293.26 g 293.26 g 293.26 g Potassium chloride 226.45 g226.45 g 226.45 g 226.45 g 226.45 g Ascorbic acid 445.94 g 445.94 g445.94 g 445.94 g 445.94 g Vitamin mineral premix 142.88 g 142.88 g142.88 g 142.88 g 142.88 g DHA oil  137.8 g  137.8 g  137.8 g  137.8 g 137.8 g Carrageenan  180.0 g  180.0 g  180.0 g  180.0 g  180.0 gMagnesium chloride  55.0 g  55.0 g  55.0 g  55.0 g  55.0 g Ferroussulfate  58.0 g  58.0 g  58.0 g  58.0 g  58.0 g Choline chloride  53.9 g 53.9 g  53.9 g  53.9 g  53.9 g Vitamin A, D₃, E, K₁ premix  47.40 g 47.40 g  47.40 g  47.40 g  47.40 g Citric acid  29.77 g  29.77 g  29.77g  29.77 g  29.77 g Probiotic 1.0 0.95 0.90 1.05 1.10 Mixed carotenoidpremix  26.40 g  26.40 g  26.40 g  26.40 g  26.40 g Sodium chloride ANAN AN AN AN L-camitine  3.31 g  3.31 g  3.31 g  3.31 g  3.31 gTricalcium phosphate  15.65 g  15.65 g  15.65 g  15.65 g  15.65 gPotassium phosphate monobasic  13.67 g  13.67 g  13.67 g  13.67 g  13.67g Riboflavin  2.42 g  2.42 g  2.42 g  2.42 g  2.42 g Potassium hydroxideAN AN AN AN AN AN = as needed

Examples 31-34

Examples 31-34 illustrate concentrated liquid human milk fortifiers ofthe present disclosure, the ingredients of which are listed in the tablebelow. All ingredient amounts are listed as kilogram per 1000 kilogrambatch of product, unless otherwise specified.

Ingredient (Per 1000 Kg) Ex. 31 Ex. 32 Ex. 33 Ex. 34 Water Q.S. Q.S.Q.S. Q.S. Casein Hydrolysate 108 108 125 150 Maltodextrin 104 104 104104 MCT Oil 17.3 17.3 17.3 17.3 Tricalcium Phosphate 16.0 16.0 16.0 16.0Soy Oil 10.4 10.4 10.4 10.4 6′ sialyllactose (6′SL) 0.0948 0.090050.0853 0.0995 Lacto-N-neotetraose 0.0948 0.09005 0.0853 0.0995Galactooligosaccharides (GOS) 6.7704 6.7704 6.7704 6.7704 Gum Arabic12.0 10.0 15.0 2.031 Starch 12.0 10.0 35.0 6.0 Coconut Oil 6.3 6.3 6.36.3 Potassium Citrate 6.9 6.9 6.9 6.9 Ascorbic Acid 2.9 2.9 2.9 2.9Magnesium Chloride 4.0 4.0 4.0 4.0 ARA oil 2.6 2.6 2.6 2.6 Leucine 1.81.8 1.8 1.8 DHA oil 2.1 2.1 2.1 2.1 Potassium Chloride 1.1 1.1 1.1 1.1Tyrosine 1.4 1.4 1.4 1.4 Monoglycerides 800 g 800 g 800 g 800 g MixedCarotenoid 551 g 551 g 551 g 551 g M-Inositol 529 g 529 g 529 g 529 gSodium Chloride 861 g 861 g 861 g 861 g L-Carnitine 221 g 221 g 221 g221 g Tryptophan 331 g 331 g 331 g 331 g Zinc Sulfate 309 g 309 g 309 g309 g Niacinamide 320 g 320 g 320 g 320 g Tocopheryl Acetate 364 g 364 g364 g 364 g Gellan Gum 200 g 300 g 400 g 600 g Ferrous Sulfate 106 g 106g 106 g 106 g Choline Chloride 353 g 353 g 353 g 353 g CalciumPantothenate 132 g 132 g 132 g 132 g Vitamin A Palmitate 77 g 77 g 77 g77 g Riboflavin 33 g 33 g 33 g 33 g Vitamin D3 13 g 13 g 13 g 13 gCopper Sulfate 18 g 18 g 18 g 18 g Pyridoxine Hydrochloride 20 g 20 g 20g 20 g Thiamin Hydrochloride 24 g 24 g 24 g 24 g Folic Acid 3.3 g 3.3 g3.3 g 3.3 g Biotin 2.5 g 2.5 g 2.5 g 2.5 g Manganese Sulfate 1.8 g 1.8 g1.8 g 1.8 g Phylloquinone 880 mg 880 mg 880 mg 880 mg Sodium Selenate 90mg 90 mg 90 mg 90 mg Cyanocobalamin 88 mg 88 mg 88 mg 88 mg PotassiumHydroxide Q.S. Q.S. Q.S. Q.S.

Example 35

In this Example, the effect of 2′-fucosyllactose (2′FL) or3′-fucosyllactose (3′FL) on stimulating enteric nerve cells in thegastrointestinal tract of rodents is analyzed.

Specifically, a peristalsis model using luminally perfused mouse colonis used to test the stimulation effect of 2′FL or 3′FL on enteric nervecells. Colon muscle is perfused with 2′FL or 3′FL, at concentrations of1 mg/mL, 0.5 mg/mL, and 0.1 mg/mL, for 15 minutes. The frequency andamplitude of contractions of the muscle is analyzed. The results areshown in FIG. 1.

As shown in the results, there is a direct stimulation of nerve cells by2′FL or 3′FL without involving gut microbiota and/or their metabolites.Specifically, the frequency and amplitude of contraction are reducedconsistently and in a dose response fashion. The results indicate that3′FL is more effective than 2′FL.

Example 36

In this Example, the fermentation rates of various non-digestiblecarbohydrates are measured.

Inclusion/exclusion criteria for choosing eight infant participantsinclude: the infant was full term at birth with a gestational age of 38to 42 weeks; the infant was at or above the fifth percentile for weightat birth; the infant has no maternal medical history of diabetes,tuberculosis, or perinatal infection with proven adverse effects on thefetus; was a vaginal birth; was at least 2 months of age at study entry,but not older than 4 months of age; has no known cardiac, respiratory,gastrointestinal, or other systemic disease such as urinary tractinfection or otitis media; is free of history of blood groupincompatibility serious enough to result in hematological problems; andis not receiving any medications (except for supplemental vitamins) andhas never received antibiotics. The eight infants are allowed to consumetheir normal diet of breast milk or infant formula. Four infants areexclusively breast fed and four infants are exclusively formula fed oneof four commercially available infant formulas.

On the day of the in vitro experiments, a fecal sample is collected inthe diaper and prepped within 15 minutes of defecation. For prepping,the sample is placed in a container with tepid water and analyzed. Fecalsamples are diluted 1:10 (wt/vol) in anaerobic dilution solution byblending for 15 seconds in a Waring blender under a stream of CO₂.Blended, diluted feces are filtered through four layers of cheeseclothand sealed in 125-mL serum bottles under CO₂. Inoculum is stored at 37°C. until inoculation of in vitro tubes.

Oligosaccharide substrates suitable for growing the bacterium includegalactooligosaccharides (GOS) 95 (GOS; Inalco Pharmaceuticals, San LuisObispo, Calif.), a-(2-6′)-N-Acetylneuraminyl-lactose sodium salt (6′SL;Inalco Pharmaceuticals, San Luis Obispo, Calif.);2′-a-L-Fucopyranosyl-D-Lactose (2′FL; Inalco Pharmaceuticals, San LuisObispo, Calif.); LNnT; Orafti® HP inulin (HP inulin) (BENEO-Orafti,Belgium); and gum arabic (Fisher Scientific, Pittsburgh, Pa.). In vitrofermentation model

Approximately 80 mg of each substrate is weighed in triplicate for eachpull time into 16-mL Balch tubes that are used in a model that simulateslarge bowel fermentation. An aliquot (7.2 mL) of medium (Table 1; FIG.2) is aseptically transferred into the Balch tubes, capped with butylrubber stoppers, and sealed with aluminum caps. Tubes containing HPinulin and gum arabic are stored at 4° C. for approximately 12 h toenable hydration of the substrates before initiating fermentation. Thesetubes are placed in a 37° C. water bath approximately 30 min beforeinoculation. Due to the cost of the substrates and difficulty inobtaining samples from infants, tubes containing GOS, 6′SL, 2′FL, andLNnT are hydrated upon obtaining a fecal sample and placed in a 37° C.water bath until inoculation.

Sample and blank tubes are aseptically inoculated with 0.8 ml of dilutedfeces. Tubes are incubated at 37° C. with periodic mixing every 2 h forup to 12 h. At 0, 3, 6, and 12 h after inoculation, tubes are removedfrom the 37° C. incubator and processed immediately for analyses. The pHof tube contents is measured with a standard pH meter. A 3-ml subsampleof fluid is collected and used for short-chain fatty acid and lactateanalyses. A 2-mL sub sample is taken and frozen at −80° C. for bacterialanalysis. Short-chain fatty acid (SCFA) analyses

The 3-mL aliquot of fluid removed from the sample tubes for SCFAanalysis is immediately added to 0.75 mL of 25% metaphosphoric acid.Concentrations of acetate, propionate, and butyrate are determined usinga Hewlett-Packard 5890A series II gas chromatograph and a glass column(180 cm×4 mm i.d.) packed with 10% SP-1200/1% H₃PO₄ on 80/100+meshChromosorb WAW (Supelco Inc., Bellefonte, Pa.). Oven temperature,detector temperature, and injector temperature are 125, 175, and 180°C., respectively. SCFA concentration values are corrected for blank tubeproduction of SCFA and 0 h concentrations for each substrate. Total SCFAare calculated as the total amount of acetate, propionate, and butyrate.

Data is analyzed as a split-split-plot in a completely randomized blockdesign using the Mixed procedure of SAS (SAS Inst., Inc., Cary, N.C.).Block is defined as the diet of the baby (breast milk or formula). Fixedeffects tested include diet, substrate, and time, and the interactionsare investigated if significant. Infant and period are included asrandom effects in the model. Means are separated using a protected LSDwith a Tukey adjustment to control for experiment-wise error. Leastsquare means are reported along with the pooled SEM for all responsecriteria. A probability of P<0.05 is accepted as statisticallysignificant.

Results and Discussion

The pH change from baseline decreases (P<0.0001) over time for allsubstrates except gum arabic (FIG. 3). At 3, 6, and 12 h afterinoculation, pH change from baseline is smallest (P<0.0001) with the gumarabic substrate, and greatest in the LNnT, 2′FL, and GOS substrates. Adecrease in pH is an indicator of fermentation, and these data arereflective of SCFA production.

Total SCFA production differs among substrates (FIG. 4) at 3, 6, and 12h of fermentation (P<0.0001). Gum arabic produces the least amount ofSCFA and does not change over time. After 3 and 6 h of fermentation,total SCFA production is lower (P<0.05) with HP inulin compared to allother substrates and is lower (P<0.05) with 6′SL compared to GOS. By 12h of fermentation, total SCFA production remains lower (P<0.05) with HPinulin relative to 2′FL, 6′SL, GOS, and LNnT substrates. Also, after 12h of fermentation, total SCFA production is greater (P<0.05) for the6′SL and GOS substrates compared to 2′FL.

Example 37

In this Example, probiotic fermentation parameters are determined forpurified HMOs, HMO precursors, and other prebiotic oligosaccharides.

Bacterial Cultures

All bifidobacteria strains are initially inoculated from frozen stocks,grown in deMan Rogosa Sharpe (MRS) broth (Difco, Detroit, MI)supplemented with 0.5 g/L L-cysteine/HC1 and incubated at 37° C. for 24h in an anaerobic chamber (90% N2, 5% CO₂ and 5% H₂). Subsequently, thecultures are passed twice on a semi-synthetic MRS medium (sMRS)+0.5 g/LL-cysteine/HCl which is supplemented with 1% (w/v) filter-sterilizedglucose as the sole carbohydrate source. After the 2nd pass, culturesare prepared to use as inoculums for growth assays described below. Allbacterial strains for use in this Example are listed in the table below.

TABLE Microorganisms Culture Collection Number Genus Species Strain  1MJM29 Bifidobacterium adolescentis ATCC 15703  2 MJM30 Bilidobacteriuminfantis S12; ATCC 15697  3 MJM32 Bifidobacterium animalis subsp. DSM10140 lactis  4 MJM33 Bifidobacterium Animalis subsp. ATCC 25527Animalis  5 MJM34 Bifidobacterium Bifidum ATCC 29521  6 MJM35Bifidobacterium Breve ATCC 15700  7 MJM37 Bifidobacterium Bifidum ATCC11617  8 MJM88 Bifidobacterium Lactis Bf-6 (Cargill)  9 MJM92Bifidobacterium Longum BB536 (Morinaga) 10 MJM93 BifidobacteriumInfantis M-63 (Morinaga) 11 MJM94 Bifidobacterium Breve M-16V (Morinaga)12 MJM95 Bifidobacterium Lactis Bb12; (Chr. Hansen)

Bacterial Growth Assays

After the 2nd pass in sMRS+glucose+cysteine, the cultures are washedonce with 10 mL of sterile sMRS+cysteine (no carbohydrate), resuspendedin 10 ml of sterile sMRS+cysteine (no carbohydrate) and then used as a1% inoculum. Carbohydrates for use in this Example are shown in thetable below. The carbohydrates are sterilized with a 0.22 micron filterand used at a 1% final concentration. Cell growth is performed in 250 uLof sMRS+cysteine covered with 50 uL of mineral oil in a Bioscreen100-well Honeycomb plate. Cell growth is monitored by measuring opticaldensity at 600 nm (0D600) using a Bioscreen C Automated MicrobiologyGrowth Curve Analysis System. The plate reader is operated indiscontinuous mode, with absorbance readings performed in 30-minuteintervals, and preceded by 30-second shaking intervals at maximum speed.Controls consist of inoculated medium lacking carbohydrate. Due to spacelimitations on the microtitre plate, the carbohydrates are divided intothree separate groups: plate A (HMO precursors: glucose, galactose,lactose, NAG, fucose, fructose and sialic acid), plate B (Prebiotics:glucose, PurimuneTM GOS, purified Purimune™ GOS, Vivinal® GOS, purifiedVivinal® GOS, scFOS and PDX), and plate C (HMOs: glucose, 6′-SL, 3′-SL,2′-FL, 3′-FL and LNnT). All three plates include a positive control(glucose) and negative control (no carbohydrate).

TABLE Carbohydrates Carbohydrate Source Dextrose (D-Glucose) FisherScientific D(+)-Galatose ACROS-ORGANICS a-Lactose Fisher ScientificL-(−) Fucose SIGMA D-Fructose ALDRICH Sialic acid (N-acetylneuraminicacid) CALBIOCHEM NAG (N-acetyl-D-glucosamine) SIGMA GOS (Purimune ™ GTCNutrition Galactooligiosaccharide) Purified GOS (Purimune ™ GTCNutrition Galactooligosaccharide) Vivinal ® GOS Friesland Foods(Galactooligosaccharide) Purified Vivinal ® GOS Friesland Foods(Galactooligosaccharide) scFOS (Short-Chain Nutraflora ® P-95Fructooligosaccharide) (GTC Nutrition) PDX (Litesse ® Polydextrose)DANISCO 6′SL (6′-sialyllactose) V-labs; SL 306 Lot#HGDX 21-163-1 3′SL(3′-sialyllactose) V-labs; SL 302 Lot#HGDX 76-161-1 2′FL(2′-fucosyllactose) V-labs; Lot#DX103 3′FL (3′-fucosyllactose) V-labs;Lot#DX807 LNnT (Lacto-N-Neotetraose) Abbott Nutrition

Bacterial Growth Curves

The OD600 data for each carbohydrate is corrected by subtracting theOD600 of the basal media (sMRS) +cysteine from the sample plate for eachprobiotic. Maximum OD is determined by inspection of the correctedgrowth data. OD is determined by subtracting the initial corrected OD(time point 0) from the maximum corrected OD. Samples are grown inbiologically independent triplicates and the resulting growth kineticdata are expressed as the mean of these replicates.

For the growth curve plots, OD600 vs. time is first plotted for thebacteria grown on medium lacking carbohydrate (sMRS). For all othercarbohydrates, the OD600 data is corrected by subtracting the OD600 ofsMRS.

Purification of GOS

Purified GOS is obtained by purification of Purimune™ GOS (GTCNutrition) and Vivinal® GOS (Friesland Foods Domo). Stock solutions of1.5 g/100 mL are applied to a XK column (XK 50/100 column, 5.0×100 cm,GE healthcare) packed with Sephadex G25 medium (Sigma). The column iseluted with pure distilled water at a rate of 8 ml/min and is collectedin 12-mL fractions by a Gilson FC 203B fraction collector.

Detection of carbohydrate in every 2-3 fractions is performed using thephenol—sulfuric acid assay. Briefly, 50 μL of sample (2 μL of fractionand 48 μL of distilled water in a well) is added to 150 n1 ofconcentrated sulfuric acid rapidly in a 96-well microtitre plateImmediately thereafter, 30 n1 of 5% phenol is added and the plate iskept in a static water bath for 30 minutes at 80° C. After cooling toroom temperature for 5 minutes, it is wiped dry and absorbance at 490 nmis measured by a SpectraMax Plus384 Spectrophotometer. Based oncarbohydrate analysis, fractions containing minimal di- andmonosaccharides are pooled and freeze dried (Freeze drysystem/Freezezone 4.5/LABCONCO) for bacterial fermentation experiments.In addition, freeze dried GOS is pooled from multiple runs in order togenerate enough purified GOS for growth experiments (5 runs withPurimuneTM GOS and 3 runs with Vivinal® GOS).

Results & Discussion GOS Purification

GOS is produced by the transgalactosylation of lactose and has been usedas a prebiotic supplement in pediatric nutrition. Due to issues with GOSsynthesis, commercial GOS products are a mixture of many differentcarbohydrates which may include mono- and disaccharides. In order totest the fermentation parameters of GOS and not the mono- anddisaccharides which would not normally reach the colon, a purified GOSfraction, essentially free of mono- and disaccharides is obtained.Glucose (monosaccharide), lactose (disaccharide) and raffinose(trisaccharide) are used as standards. Consistent with information fromthe suppliers, Purimune™ GOS has less mono- and disaccharides thanVivinal® GOS. For example, the Purimune™ GOS peaks before the raffinosepeak suggesting that Purimune™ GOS consists primarily of trisaccharidesor larger. For Vivinal® GOS, the peak is observed at a similar fractionnumber as lactose. Since lactose begins to appear in fraction 55,fractions 30 through 55 are used as the purified GOS from bothsuppliers.

HMO Precursor Fermentation

All bifidobacteria tested grow very little in the basal media(sMRS+cysteine) (FIG. 5A), whereas they all grow well in glucose (FIG.5B). In general, the bifidobacteria, which is not able to fermentgalactose (FIG. 5C), also has reduced growth on lactose (FIG. 5D). Noneof the bifidobacteria are able to ferment L-fucose (FIG. 5E) or sialicacid (FIG. 5F), two key constituents of HMOs and mucin. Only B. breveATCC 15700 is able to ferment NAG (FIG. 5G), a key component of HMOs andmucin. Lastly, the majority of bifidobacteria is able to fermentfructose (FIG. 5H).

Prebiotic Fermentation

Removal of mono- and disaccharides from Purimune™ GOS results in adecrease in growth for all bifidobacteria (FIG. 6A). In fact, B. lactisDSM 10140, B. animalis ATCC 25527, B. bifidum ATCC 29521, B. lactis Bf-6and B. longum are not able to ferment the purified Purimune™ GOS (FIG.6D). A similar pattern is seen with purified Vivinal® GOS (FIG. 6F),except more growth is seen with Vivinal® GOS than PurimuneTM GOS. Inorder to mimic the colonic situation, the free mono-and disaccharidespresent in these products need to be removed. Also, it is clear thatPurimune™ GOS has a higher relative concentration of oligosaccharides.Both B. infantis strains are among the best growers on purified GOS asdetermined by 40D, confirming that GOS is a reasonable prebiotic to addto infant formula if the goal is to increase B. infantis. Allbifidobacteria tested, except for B. animalis ATCC 25527, are able toferment scFOS (FIG. 6G), whereas no bifidobacteria are able to fermentpolydextrose (PDX) (FIG. 6H).

HMO Fermentation

Only B. infantis ATCC 15697 and B. infantis M-63 are able to ferment6′-SL, 3′-SL, 2′-FL and 3′-FL (FIG. 7C-7F). In all cases, B. infantisM-63 grows better than B. infantis ATCC 15697. On the more complex LNnT(FIG. 7G), B. breve ATCC 15700 and the two B. infantis strains grow wellbut not B. breve M16-V. In addition, the ability of the two B. infantisstrains to ferment HMOs correlates with the abundance of B. infantisfound in breast fed infants. Curiously, both B. infantis strains are notable to ferment fucose or sialic acid.

Conclusions

There are significant differences amongst the tested bifidobacteriastrains regarding their abilities to ferment HMO precursors, prebioticsand HMOs. Of the 12 bifidobacteria strains tested, none are able toferment sialic acid. Regarding prebiotics, most of the bifidobacteriaare able to ferment GOS and scFOS, but they are not able to ferment PDX.Amongst the bifidobacteria strains tested, only B. infantis ATCC 15697and B. infantis M-63 are able to ferment 6′-SL, 3′-SL, 2′-FL and 3′-FL.B. breve ATCC 15700, B. infantis ATCC 15697 and B. infantis M-63 areable to ferment LNnT.

Example 38

In this Example, the ability of Lacto-N-neotetraose (LNnT),2′-Fucosyllactose (2′FL), and 6′-Sialyllactose (6′SL) to protect againstfeeding intolerance and necrotizing enterocolitis (NEC) by inducingepithelial cell differentiation and barrier function (cell resistance),promoting digestive function, promoting antibacterial function areevaluated using cell culture models of the human small intestine. Theability of LNnT, 2′FL, and 6′SL to exert these protective and beneficialeffects is evaluated using in vitro cultures representing various phasesof the differentiated intestinal epithelium. Epithelial cells arecultured in the presence of various concentrations of LNnT, 2′FL, 6′SLor a control oligosaccharide of each of these human milkoligosaccharides (HMOs) and the impact of the LNnT, 2′FL, 6′SL orcontrols on cell differentiation, barrier function, digestive function,and protection from bacteria is measured.

In a first experiment, HT-29 cells, which model the immature epithelialcells of the small intestine, were incubated in a humidified atmosphereof 5% carbon dioxide at 37° C. in the presence of LNnT or 2′FL atconcentrations of 0 mg/L (“0”), 20 mg/L (“20”), 200 mg/L (“200”), and2000 mg/L (“2000”) or in the presence of 6′SL at concentrations of 0mg/mL (“0”), 40 mg/mL (“40”), 400 mg/mL (“400”), and 4000 mg/mL (“4000”)for 72 hours. The culture medium utilized is Dulbecco's Modified EagleMedium (Life Technologies, Foster City Calif.) supplemented with 10%fetal calf serum and 2 mM glutamine The controls (“energy”) consisted of91.5 mg lactose and 64.2 mg N-acetyllactosamine/L for LNnT; 133 mglactose and 67 mg fucose/L for 2′FL; and 195 mg lactose and 205 mg/Lsialic acid for 6′SL. The impact of the LNnT, 2′FL, and 6′SL at variouslevels and the controls on the alkaline phosphatase activity permilligram of protein for HT-29 cells is measured. Alkaline phosphataseactivity is important for nutrient digestion, important for breakdown ofthe harmful bacteria lipopolysaccharide molecules that induceinflammation, and is a marker of cell differentiation. The results ofthe measurements are shown in FIGS. 8-10, which indicate that there is asignificant increase in alkaline phosphatase activity (and thus anincrease in cell differentiation, digestive function, and protectionagainst harmful effects of bacteria) at the high dose of 2′FL, a trendtoward an increase in cells treated with LNnT, and no apparent effect oncells treated with 6′SL.

FIGS. 11-13 illustrate the effect of LNnT, 2′FL, and 6′SL on cellresistance (transepithelial resistance), which is a marker forepithelial barrier function, wherein a higher resistance is associatedwith a higher barrier function. Epithelial cell resistance or barrierfunction is a measure of differentiated epithelial cell function.Specifically, as the cells mature, tighter junctions between the cellsare formed resulting in a stronger epithelial cell barrier. This barrierprevents the movement of large molecules, bacteria, or viruses from oneside of the barrier to the other, which could improve resistance toinfection, sepsis, and NEC. Transepithelial resistance is measured usingTranswell Snapwell inserts containing the desired cell culture and aretransferred to modified Ussing chambers and bathed in modified Kreb'ssolution at 37° C. with 95% oxygen and 5% carbon dioxide.Transepithelial resistance is measured as the passive transport of ionsacross the monolayers.

In a second experiment, Caco-2 cells, which model more mature epithelialcells of the small intestine, were incubated in a humidified atmosphereof 5% carbon dioxide at 37° C. in the presence of LNnT or 2′FL atconcentrations of 0 mg/L (“0”), 20 mg/L (“20”), 200 mg/L (“200”), and2000 mg/L (“2000”) or in the presence of 6′SL at concentrations of 0mg/mL (“0”), 40 mg/mL (“40”), 400 mg/mL (“400”), and 4000 mg/mL (“4000”)for 72 hours. The culture medium utilized was Dulbecco's Modified EagleMedium (Life Technologies, Foster City Calif.) supplemented with 10%fetal calf serum and 2 mM glutamine The controls (“energy”) consisted of91.5 mg lactose and 64.2 mg N-acetyllactosamine/L for LNnT; 133 mglactose and 67 mg fucose/L for 2′FL; and 195 mg lactose and 205 mgsialic acid/L for 6′SL. The impact of the LNnT, 2′FL, and 6′SL atvarious levels and the controls on the alkaline phosphatase activity isimportant for nutrient digestion, for breakdown of the harmful bacteriallipopolysaccharide molecules that induce inflammation, and is a markerof cell differentiation. For these reasons, intestinal tissue withgreater alkaline phosphatase activity would be expected to be moreresistant to inflammation and NEC. The results of the measurements areshown in FIGS. 14-16, which indicate that there is a trend towardincreased alkaline phosphatase activity (and thus an increase in celldifferentiation, digestive function, and protection against harmfuleffects of bacteria) in 2′FL treat cultures, a trend toward an increasein cells treated with LNnT, and no apparent effect on cells treated with6′ SL.

The impact of LNnT, 2′FL, and 6′SL at various levels and the controls onthe sucrase activity per milligram of protein for Caco-2 cells ismeasured as another indication of digestive function. The results of themeasurements areshown in FIGS. 17-19, which indicate that there is atrend toward sucrase activity (and thus an increase in digestivefunction) in 2′FL treated cultures, and no apparent effect on cellstreated with LNnT or 6′SL.

FIGS. 20-22 illustrate the effect of LNnT, 2′FL, and 6′SL on cellresistance (transepithelial resistance), which is a marker forepithelial barrier function, wherein a higher resistance is associatedwith a higher barrier function. Epithelial cell resistance or barrierfunction is a measure of differentiated epithelial cell function.Specifically, as the cells mature, tighter junctions between the cellsare formed resulting in a stronger epithelial cell barrier. This barrierprevents the movement of large molecules, bacteria, or viruses from oneside of the barrier to the other, which could improve resistance toinfection, sepsis, and NEC. The results indicate that LNnT can have apositive effect on cell resistance for more mature Caco-2 cells.Transepithelial resistance was measured using Transwell Snapwell insertscontaining the desired cell culture and were transferred to modifiedUssing chambers and bathed in modified Kreb's solution at 37C with 95%oxygen and 5% carbon dioxide. Transepithelial resistance was measured asthe passive transport of ions across the monolayers.

Conclusions

The data reported in FIGS. 8-22 indicate that LNnT and 2′FL promoteintestinal functions including digestion, barrier function, andprotection against bacterial components that are known to induceinflammation. Promotion of digestive function, through increaseddigestive enzyme activities (sucrase and alkaline phosphatase) can helpprevent or reduce the severity of feeding intolerance. Combined witheffects on barrier function and protection against harmful bacterialmetabolites, these data provide ample evidence that these HMOs couldhelp protect against intestinal inflammation and NEC.

Example 39

In this Example, the effect of HMOs, and the dose-dependency thereof, onincreasing the expression of TFF3 and other goblet cell genes thatpromotefeeding tolerance through enhanced gastrointestinal barrierfunction and healing by HMOs is analyzed.

Pooled HMOs are tested with respect to their ability to induce MUC2,TFF3, RELMβ, CHST5, and GAL3ST2 expression in the human LS174T cellculture model of goblet cells. The human LS174T colorectal cancer cellline is obtained from the American Type Culture Collection (ATCC).LS174T cells are maintained in minimum essential medium (MEM)supplemented with 10% Fetalplex (Gemini Biosciences), 1.5 g/L of Na₂CO₃,10 ml/L penicillin G-streptomycin solution (Gemini Bio-products) at 37°C. in 5% CO₂. Pooled HMOs are obtained from Lars Bode (University ofCalifornia, San Diego) and dissolved in cell culture grade water torequired concentration. The solution is subsequently filter sterilizedand used for cell culture studies. LS174T cells are treated with themedia described above containing 0, 1, or 5 mg HMO/mL.

LS174T cells are collected and suspended in Trizol reagent and total RNAis isolated using the RNeasy Plus Kit (Qiagen) according to themanufacturer's instructions. The quality and quantity of RNA isolatesare determined by Nanodrop (Thermo Fisher Scientific). RNA isolates arereverse transcribed using the High Capacity cDNA Reverse TranscriptionKit (Applied Biosystems) to create cDNA, which is to assess geneexpression via quantitative PCR.

For quantitative RT-PCR, specific TaqMAN gene expression assays areobtained from Applied Biosystems, which include expression assays forMUC2 (Hs00159374_m1), TFF3 (Hs00173625_m1), RELMβ (Hs00395669_m1), CHST5(Hs00375495_m1), GAL3ST2 (Hs00223271_m1) and GUSB (Hs99999908_m1).Quantitative real-time PCR is performed using TaqMAN PCR Master Mix(Applied Biosystems). Reactions are run in duplicates in a 384-wellplate using an Applied Biosystems 7900HT Fast Real-Time PCR System. Theresults are analyzed using SDS 2.3 software and calculated by deltadelta Ct method. All samples are normalized to Gus-13 expression andfold induction is calculated over untreated controls. Gene expression isexpressed as fold increase compared to HMO-free control cells. Theexperiment is repeated three times. Data represent means+SEM (n=3 platesper experiment). Statistical differences are indicated by differentletters (P<0.05).

FIGS. 23A-23E represent the combined results of three replicateexperiments. Specifically, FIGS. 23A, 23B, and 23C illustrate that thetreatment with HMOs at a level of at least 1 mg/mL increases theexpression of the MUC2, TFF3, and RELMβ genes compared to controlcultures. Increased expression of goblet cell genes is specific and notuniversal, as evidenced by the minimal induction or lack of induction ofCHST5 and GAL3ST2, respectively, by treatment with HMOs at either 1mg/mL or 5 mg/mL.

In addition, FIGS. 23A and 23B indicate a dose dependent increase inexpression of MUC2 and TFF3, with a modest induction (−1.5 fold) notedat the 1 mg/mL treatment level and more pronounced increases (−2 fold)at 5 mg/mL. In addition, the expression levels of RELMβ (FIG. 23C) wereincreased (−1.5 fold) at each of the 1 mg/mL treatment level and the 5mg/mL treatment level. In contrast, gene expression of CHST5 (FIG. 23D)and GAL3ST2 (FIG. 23E) is not significantly impacted at any dose. Assuch, it can be concluded that the impact of HMOs on expression ofseveral genes involved in the healing response of the gastrointestinaltract is dose-dependent.

These results indicate that HMOs promote the expression of several genesinvolved in GI barrier function and in the healing response of the GItract. First, the protein products of the MUC2, TFF3, and RELMβ genes,each of which was induced by HMOs, work synergistically to create themucus barrier that protects the GI tract from pathogens. Also,expression of TFF3 has been positively associated with prevention andrestitution of gastrointestinal damage to the epithelial cells in theintestine of mammals. Oral treatment with TFF3 reduces the damageassociated with different forms of colitis in animal models.Additionally, HMOs induce the expression of MUC2, which provides abarrier that protects the gastrointestinal tract from infection andother sources of injury. Further, HMOs induce the expression of RELMβ,which is a protein associated with resolution of inflammation. Becausetissue damage is difficult to heal when inflammation is abundant, theinflammation resolving effects of RELMβ induced by HMOs also supportshealing. The combinedimpact of HMOs on expression of TFF3, MUC2, andRELMβ enables a product to prevent necrotizing enterocolitis and supportwound healing through its synergistic effects on cell healing,resolution of inflammation and promotion of barrier function.

1.-22. (canceled)
 23. A method of improving the feeding tolerance of aninfant, toddler, or child, the method comprising administering to aninfant, toddler, or child in need thereof a nutritional compositioncomprising at least one human milk oligosaccharide selected from thegroup consisting of 2′-fucosyllactose, lacto-N-neotetraose, andcombinations thereof in a total amount of from about 0.001 mg/mL toabout 20 mg/mL.
 24. The method of claim 23, wherein the compositioncomprises from 0.001 mg/mL to less than 2 mg/mL of 2′-fucosyllactose.25. The method of claim 23, wherein the composition comprises from 0.001mg/mL to less than 0.2 mg/mL of lacto-N-neotetraose.
 26. The method ofclaim 23, wherein the at least one human milk oligosaccharide is presentin a total amount of from about 0.001 mg/mL to less than 2 mg/mL. 27.The method of claim 23, wherein the nutritional composition furthercomprises at least one of a probiotic, a long chain polyunsaturatedfatty acid, an antioxidant, a milk protein of human origin, and a milkprotein of bovine origin.
 28. The method of claim 23, wherein thenutritional composition further comprises at least one of3′-sialyllactose, 6′-sialyllactose, and combinations thereof.
 29. Themethod of claim 23, wherein the nutritional composition furthercomprises at least one of inulin, a gum, polydextrose, and combinationsthereof.
 30. A method of improving the feeding tolerance of an infant,toddler, or child, the method comprising administering to an infant,toddler, or child in need thereof a nutritional composition comprising2′-fucosyllactose and 6′-sialyllactose, wherein the 2′-fucosyllactoseand 6′-sialyllactose are present in a total amount of from about 0.001mg/mL to about 20 mg/mL.
 31. The method of claim 30, wherein thenutritional composition further comprises a fructooligosaccharide. 32.The method of claim 31, wherein the fructooligosaccharide is present inan amount of about 0.001 mg/mL to about 20 mg/mL.
 33. The method ofclaim 32, wherein the nutritional composition comprises from 0.001 mg/mLto less than 0.25 mg/mL of 6′-sialyllactose.
 34. The method of claim 33,wherein the nutritional composition comprises from greater than 0.4mg/mL to 10 mg/mL of 6′-sialyllactose.
 35. The method of claim 32,wherein the nutritional composition comprises from 0.001 mg/mL to lessthan 2 mg/mL of 2′-fucosyllactose.
 36. The method of claim 32, whereinthe nutritional composition further comprises at least one of aprobiotic, a long chain polyunsaturated fatty acid, an antioxidant, amilk protein of human origin, a milk protein of bovine origin, and amilk protein of combined bovine and human origin.
 37. The method ofclaim 36, wherein the nutritional composition further comprises at leastone of inulin, a gum, polydextrose, and combinations thereof.
 38. Asynthetic formula for improving the feeding tolerance of an infant,toddler, or child, the synthetic formula comprising from about 0.001mg/mL to about 20 mg/mL of an oligosaccharide blend, wherein theoligosaccharide blend comprises a first oligosaccharide selected fromthe group consisting of a fructooligosaccharide, 2′-fucosyllactose, andcombinations thereof a second oligosaccharide selected from the groupconsisting of 3′-sialyllactose, 6′-sialyllactose, and combinationsthereof.
 39. The synthetic formula of claim 38, wherein the firstoligosaccharide comprises a combination of a fructooligosaccharide and2′-fucosyllactose.
 40. The synthetic formula of claim 38, wherein thesecond oligosaccharide is 6′-sialyllactose.
 41. The synthetic formula ofclaim 38, further comprising a third oligosaccharide selected from thegroup consisting of inulin, a gum, polydextrose, and combinationsthereof.
 42. The synthetic formula of claim 38, wherein the firstoligosaccharide comprises 2′-fucosyllactose in a concentration of from0.001 mg/mL to less than 2.0 mg/mL and the second oligosaccharidecomprises 6′-sialyllactose in a concentration of from 0.001 mg/mL toless than 0.25 mg/mL.